<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Tramadol for osteoarthritis - Toupin April, K - 2019 | Cochrane Library</title> <meta content="Tramadol for osteoarthritis - Toupin April, K - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005522.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Tramadol for osteoarthritis - Toupin April, K - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005522.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005522.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Tramadol for osteoarthritis" name="citation_title"/> <meta content="Karine Toupin April" name="citation_author"/> <meta content="ktoupin@cheo.on.ca" name="citation_author_email"/> <meta content="Jacinthe Bisaillon" name="citation_author"/> <meta content="Children's Hospital of Eastern Ontario Research Institute" name="citation_author_institution"/> <meta content="Vivian Welch" name="citation_author"/> <meta content="Lara J Maxwell" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Peter Jüni" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Anne WS Rutjes" name="citation_author"/> <meta content="M Elaine Husni" name="citation_author"/> <meta content="Cleveland Clinic: Orthopedic and Rheumatologic Institute" name="citation_author_institution"/> <meta content="Jennifer Vincent" name="citation_author"/> <meta content="Children's Hospital of Eastern Ontario Research Institute" name="citation_author_institution"/> <meta content="Tania El Hindi" name="citation_author"/> <meta content="Children's Hospital of Eastern Ontario Research Institute" name="citation_author_institution"/> <meta content="George A Wells" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Peter Tugwell" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD005522.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/05/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005522.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005522.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005522.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; Arthritis, Rheumatoid [drug therapy]; Drug Therapy, Combination; Osteoarthritis [*complications, drug therapy]; Osteoarthritis, Knee [drug therapy]; Pain [*drug therapy, etiology, prevention &amp; control]; Pain Management; Pain Measurement; Tramadol [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005522.pub3&amp;doi=10.1002/14651858.CD005522.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005522\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005522\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","pt","ms","fr","zh_HANS","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005522.pub3",title:"Tramadol for osteoarthritis",firstPublishedDate:"May 27, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005522.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005522.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005522.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005522.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005522.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005522.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005522.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005522.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005522.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005522.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11941 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005522.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/appendices#CD005522-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/table_n/CD005522StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/table_n/CD005522StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Tramadol for osteoarthritis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Karine Toupin April</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0003">Jacinthe Bisaillon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0004">Vivian Welch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0005">Lara J Maxwell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0006">Peter Jüni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0007">Anne WS Rutjes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0008">M Elaine Husni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0009">Jennifer Vincent</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0010">Tania El Hindi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0011">George A Wells</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information#CD005522-cr-0012">Peter Tugwell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information/en#CD005522-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 May 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005522.pub3">https://doi.org/10.1002/14651858.CD005522.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005522-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005522-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005522-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005522-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005522-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005522-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005522-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005522-abs-0001" lang="en"> <section id="CD005522-sec-0001"> <h3 class="title" id="CD005522-sec-0001">Background</h3> <p>Tramadol is often prescribed to treat pain and associated physical disability in osteoarthritis (OA). Due to the pharmacologic mechanism of tramadol, it may lead to fewer associated adverse effects (i.e. gastrointestinal bleeding or renal problems) compared to non‐steroidal anti‐inflammatory drugs (NSAIDs). This is an update of a Cochrane Review originally published in 2006. </p> </section> <section id="CD005522-sec-0002"> <h3 class="title" id="CD005522-sec-0002">Objectives</h3> <p>To determine the benefits and harms of oral tramadol or tramadol combined with acetaminophen or NSAIDs in people with osteoarthritis. </p> </section> <section id="CD005522-sec-0003"> <h3 class="title" id="CD005522-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase databases, as well as the US National Institutes of Health and World Health Organization trial registries up to February 2018. We searched the LILACS database up to August 2015. </p> </section> <section id="CD005522-sec-0004"> <h3 class="title" id="CD005522-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) that evaluated the effect of tramadol, or tramadol in combination with acetaminophen (paracetamol) or NSAIDs versus placebo or any comparator in people with osteoarthritis. </p> </section> <section id="CD005522-sec-0005"> <h3 class="title" id="CD005522-sec-0005">Data collection and analysis</h3> <p>We used standard methodologic procedures expected by Cochrane.</p> </section> <section id="CD005522-sec-0006"> <h3 class="title" id="CD005522-sec-0006">Main results</h3> <p>We included 22 RCTs (11 more than the previous review) of which 21 RCTs were included in meta‐analyses for 3871 participants randomized to tramadol alone or tramadol in combination with another analgesic and 2625 participants randomized to placebo or active control. Seventeen studies evaluated tramadol alone and five evaluated tramadol plus acetaminophen. Thirteen studies used placebo controls and eleven studies used active controls (two trials had both placebo and active arms). The dose of tramadol ranged from 37.5 mg to 400 mg daily; all doses were pooled. Most trials were multicenter with a mean duration of two months. Participants were predominantly women with hip or knee osteoarthritis, with a mean age of 63 years and moderate to severe pain. There was a high risk of selection bias as only four trials reported both adequate sequence generation and allocation concealment. There was a low risk for performance bias as most studies blinded participants. There was a high risk of attrition bias as 10/22 trials showed incomplete outcome data. Most of the trials were funded by the pharmaceutical industry. </p> <p>Moderate quality evidence (downgraded due to risk of bias) indicated that tramadol alone and in combination with acetaminophen had no important benefit on pain reduction compared to placebo control (tramadol alone: 4% absolute improvement, 95% confidence interval (CI) 3% to 5%; 8 studies, 3972 participants; tramadol in combination with acetaminophen: 4% absolute improvement, 95% CI 2% to 6%; 2 studies, 614 participants). </p> <p>Fifteen out of 100 people in the tramadol group improved by 20% (which corresponded to a clinically important difference in pain) compared to 10/100 in the placebo group (5% absolute improvement). Twelve out of 100 people improved by 20% in the tramadol in combination with acetaminophen group compared to 7/100 in the placebo group (5% absolute improvement). </p> <p>Moderate quality evidence (downgraded due to risk of bias) indicated that tramadol alone and in combination with acetaminophen led to no important benefit in physical function compared to placebo (tramadol alone: 4% absolute improvement, 95% CI 2% to 6%; 5 studies, 2550 participants; tramadol in combination with acetaminophen: 4% absolute improvement, 95% CI 2% to 7%; 2 studies, 614 participants). </p> <p>Twenty‐one out of 100 people in the tramadol group improved by 20% (which corresponded to a clinically important difference in physical function) compared to 16/100 in the placebo group (5% absolute improvement). Fifteen out of 100 people improved by 20% in the tramadol in combination with acetaminophen group compared to 10/100 in the placebo group (5% absolute improvement). </p> <p>Moderate quality evidence (downgraded due to risk of bias) indicated that, compared to placebo, there was a greater risk of developing adverse events with tramadol alone (risk ratio (RR) 1.34, 95% CI 1.24 to 1.46; 4 studies, 2039 participants) and tramadol in combination with acetaminophen compared to placebo (RR 1.91, 95% CI 1.32 to 2.76; 1 study, 308 participants). This corresponded to a 17% increase (95% CI 12% to 23%) with tramadol alone and 22% increase (95% CI 8% to 41%) with tramadol in combination with acetaminophen. </p> <p>The three most frequent adverse events were nausea, dizziness and tiredness. Moderate quality evidence (downgraded due to risk of bias) indicated that there was a greater risk of withdrawing from the study because of adverse events with tramadol alone compared to placebo (RR 2.64, 95% CI 2.17 to 3.20; 9 studies, 4533 participants), which corresponded to a 12% increase (95% CI 9% to 16%). </p> <p>Low quality evidence (downgraded due to risk of bias and inconsistency) indicated that there was a greater risk of withdrawing from the study because of adverse events with tramadol in combination with acetaminophen compared to placebo (RR 2.78, 95% CI 1.50 to 5.16; 2 studies, 614 participants), which corresponded to a 8% absolute improvement (95% CI 2% to 19%). </p> <p>Low quality evidence (downgraded due to risk of bias and imprecision) indicated that there was a greater risk of developing serious adverse events with tramadol alone compared to placebo (110/2459 participants with tramadol compared to 22/1153 participants with placebo; RR 1.78, 95% CI 1.11 to 2.84; 7 studies, 3612 participants), which corresponded to a 1% increase (95% CI 0% to 4%). There were no serious adverse events reported in one small study (15 participants) of tramadol with acetaminophen compared to placebo. </p> </section> <section id="CD005522-sec-0007"> <h3 class="title" id="CD005522-sec-0007">Authors' conclusions</h3> <p>Moderate quality evidence indicates that compared to placebo, tramadol alone or in combination with acetaminophen probably has no important benefit on mean pain or function in people with osteoarthritis, although slightly more people in the tramadol group report an important improvement (defined as 20% or more). Moderate quality evidence shows that adverse events probably cause substantially more participants to stop taking tramadol. The increase in serious adverse events with tramadol is less certain, due to the small number of events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005522-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005522-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005522-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005522-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005522-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005522-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005522-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005522-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD005522-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005522-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005522-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005522-abs-0005" lang="en"> <h3>Tramadol for osteoarthritis</h3> <p>This summary of a Cochrane Review presents what we know from research about the benefits and harms of tramadol (a pain reliever) for treating osteoarthritis (OA). We examined the published research up to 1 February 2018 and found 22 studies involving 3871 people taking tramadol and 2625 people in a comparator group. Compared with placebo (dummy treatment), moderate quality evidence showed that taking tramadol for up to three months had no important benefit on mean pain or function, although slightly more people in the tramadol group reported an important improvement (defined as 20% or more). Also, people may have had more side effects that them to stop taking it, such as nausea, vomiting, dizziness, constipation, tiredness and headache. We were less certain of the risk of serious effects due to the small number of events. Most of the trials were funded by the pharmaceutical industry. </p> <p><b>What is osteoarthritis and what is tramadol?</b> </p> <p>OA is a disease of the joints, such as the knee or hip. When the joint loses cartilage, the bone grows to try and repair the damage. Instead of making things better, the bone grows abnormally and makes things worse. For example, the bone can make the joint painful and unstable. This can affect physical function or ability to use the knee. </p> <p>Tramadol is an opioid used to treat OA. Unlike other pain relievers such as non‐steroidal anti‐inflammatory drugs (NSAIDs), it does not cause bleeding in the stomach and intestines, or kidney problems. It also does not affect the cartilage at the end of the bones. However, tramadol may not decrease swelling. </p> <p><b>What are the results of this review?</b> </p> <p>People in the 22 included trials took various daily doses of tramadol or a placebo, an NSAID or a different pain reliever. Most of them were women, with an average age of 63 years, and with moderate to severe pain. The length of the studies ranged from one week to three months. The results below are for tramadol alone compared to placebo. There were similar results for tramadol in combination with acetaminophen. </p> <p><b>Pain</b> (0 to 100 visual analog scale (VAS); lower scores mean less pain) </p> <p>People who took tramadol alone rated their pain to be four points lower than placebo (4% absolute improvement). People who took tramadol alone rated their pain to be 50.3; people who took a placebo rated their pain to be 54.3. </p> <p>Ten percent of people who took placebo had a clinically important improvement (at least 20%) in pain and 15% who took tramadol group had a clinically important improvement (5% more people). </p> <p><b>Physical function</b> (Western Ontario and McMaster Universities Arthritis Index (WOMAC) 0 to 1700 scale; lower scores mean better physical function) </p> <p>People who took tramadol alone rated their physical function to be 68 points lower than placebo (4% absolute improvement). People who took tramadol alone rated their physical function to be 991; people who took placebo rated their physical function to be 1059. </p> <p>Twenty‐one percent of people who took tramadol had a clinically important improvement in physical function and 16% of people who took placebo had a clinically important improvement (5% more people). </p> <p><b>Total side effects</b> </p> <p>Sixty‐six out of 100 people may have had side effects when taking tramadol alone compared to 49 out of 100 people when taking a placebo (17% more people). </p> <p><b>Withdrawals from study due to side effects</b> </p> <p>Nineteen out of 100 people withdrew from the study because of side effects when taking tramadol alone compared to seven out of 100 people when taking a placebo (12% more people). </p> <p><b>Serious side effects</b> <br/> Three out of 100 people had serious side effects when taking tramadol alone compared to two out of 100 people when taking a placebo (1% more people). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005522-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005522-sec-0111"></div> <h3 class="title" id="CD005522-sec-0112">Implications for practice</h3> <section id="CD005522-sec-0112"> <p>Based on moderate quality evidence, tramadol alone or in combination with acetaminophen probably has no important benefit on mean pain intensity or physical function over placebo in people with osteoarthritis. However, there were slightly more people in the tramadol group who achieved a clinically important response. Moderate quality evidence shows that adverse events probably cause substantially more participants to stop taking tramadol. The increase in serious adverse events with tramadol is less certain, due to the small number of events. Use of tramadol for osteoarthritis needs to consider the limited benefits with the likelihood of increasing the adverse effects.  </p> </section> <h3 class="title" id="CD005522-sec-0113">Implications for research</h3> <section id="CD005522-sec-0113"> <p>There is a need to study propensity for abuse in a more systematic method since it is rarely reported in trials.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005522-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005522-sec-0029"></div> <div class="table" id="CD005522-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tramadol alone compared with placebo for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tramadol alone compared with placebo for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> osteoarthritis of the hip or knee, or both </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: 0–100‐mm VAS pain intensity where 0 = no pain </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 54.3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 4 points lower (3 lower to 5 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3972 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 4% absolute improvement (95% CI 3% to 5% improvement),<sup>b</sup> 7% relative improvement (6% to 9% improvement), </p> <p>SMD –0.25 (95% CI –0.32 to –0.18)<sup>f</sup> </p> <p>NNTB 13 (95% CI 10 to 18)<sup>g</sup> </p> <p>A cross‐over study (Thorne 2008), which was not included in the meta‐analyses, showed improvement in pain in the intervention group compared to the placebo group (mean ± SD: 189.0 ± 105.0 versus 230.0 ± 115.4; P = 0.00). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (3 more to 6 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (95% CI 1.30 to 1.60)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: WOMAC Physical Function (scale 0 to 1700) </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was 1059</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was 68 points lower (41 lower to 99 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2550 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean function: 4% absolute improvement (95% CI 2% to 6% improvement),<sup>b</sup> 6% relative improvement (95% CI 4% to 9% improvement),<sup>f</sup> </p> <p>SMD –0.20 (95% CI –0.29 to –0.12),</p> <p>NNTB 13 (95% CI 9 to 21)<sup>g</sup> </p> <p>A cross‐over study (Thorne 2008), which was not included in the meta‐analyses, showed improvement in physical function in the intervention group compared to the placebo group (mean ± SD: 632.4 ± 361.3 vs 727.4 ± 383.4; P = 0.02). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (3 more to 8 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b> (95% CI 1.19 to 1.50)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse events</b> </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>492 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>659 per 1000</b><br/> (610 to 718) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b> <br/> (95% CI 1.24 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2039 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17% absolute worsening (95% CI 12% more to 23% more),</p> <p>34% relative worsening (95% CI 24% more to 46% more),</p> <p>NNTH 6 (95% CI 5 to 9)</p> <p>A cross‐over study (Thorne 2008), which was not included in the meta‐analyses, showed that there was little or no difference in the total number of adverse events between the intervention group (79.8%) and placebo group (65.9%) (P = 0.08). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b><br/> (159 to 235) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.64</b> <br/> (95% CI 2.17 to 3.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4533 (9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12% absolute worsening (95% CI 9% more to 16% more),</p> <p>164% relative worsening (95% CI 117% more to 220% more),</p> <p>NNTH 9 (95% CI 7 to 12)</p> <p>In a cross‐over study (Thorne 2008), which was not included in the meta‐analyses, 15 participants withdrew after randomization due to adverse events, 12 of which were in the intervention group at the time of withdrawal. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (21 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> <br/> (95% CI 1.11 to 2.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3612 (7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% absolute worsening (95% CI 0% more to 4% more),</p> <p>78% relative worsening (95% CI 11% more to 184% more),</p> <p>NNTH 68 (95% CI 29 to 477)</p> <p>In a cross‐over study (Thorne 2008), which was not included in the meta‐analyses, 1 serious adverse event occurred in a participant in the intervention group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RCT:</b> randomized controlled trial;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference; <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMDs and SEs, and binary outcomes expressed as RRs. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute improvement on a common scale (e.g. 100 mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level due to unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the CMSG Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>).<br/> <sup>h</sup>Downgraded one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005522-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with placebo for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen compared with placebo for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol in combination with acetaminophen </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 100 where 0 = no pain) </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 48.3 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 4 points lower (2 lower to 6 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>614 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 4% absolute improvement (95% CI 2% to 6% improvement),b</p> <p>8% relative improvement (95% CI 4% to 12% improvement),<sup>f</sup> </p> <p>SMD –0.28 (95% CI –0.45 to –0.12), NNTB 14 (95% CI 9 to 33)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (2 more to 9 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> (95% CI 1.29 to 2.29)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: self‐report questionnaire WOMAC Physical Function (scale 0 to 10, where 0 = no limitation) </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was</p> <p>5.9 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was 0.4 points lower (0.2 lower to 0.7 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>614 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean function: 4% absolute improvement (95% CI 2% to 7% improvement),<sup>b</sup> </p> <p>7% relative improvement (95% CI 3% to 12% improvement),<sup>f</sup> </p> <p>SMD –0.27 (95% CI –0.43 to –0.11), NNTB 12 (95% CI 8 to 30)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (2 more to 9 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (95% CI 1.20 to 1.90)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>447 per 1000</b><br/> (309 to 646) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.91</b> (95% CI 1.32 to 2.76)<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22% absolute worsening (95% CI 8% more to 41% more),</p> <p>91% relative worsening (95% CI 32% more to 176% more),</p> <p>NNTH 5 (95% CI 3 to 14)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b><br/> (68 to 235) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.78</b> </p> <p>(95% CI 1.50 to 5.16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8% absolute worsening (95% CI 2% more to 19% more),</p> <p>178% relative worsening (95% CI 50% more to 416% more),</p> <p>NNTH 13 (95% CI 6 to 44)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported: not estimable, NNTH not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference; <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute improvement on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level due to unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>The relative improvement percentage was defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>).<br/> <sup>h</sup>Downgraded one level for imprecision (wide CI).<br/> <sup>i</sup>Downgraded two levels for serious for imprecision (no events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005522-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tramadol alone compared with acetaminophen for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol alone compared with acetaminophen for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> acetaminophen </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>acetaminophen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 100 where 0 = no pain) </p> <p>Follow‐up: 1 week</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 38 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 2 higher (12 lower to 16 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 2% absolute worsening (95% CI 16% worsening to 12% improvement),<sup>b</sup> 5% relative worsening (95% CI 42% worsening to 32% improvement),<sup>g</sup> </p> <p>SMD 0.13 (–0.80 to 1.06),</p> <p>NNTB not applicable<sup>h</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 less out of 100 (8 less to 20 more)in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (95% CI 0.11 to 3.22)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: 1 week</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.00</b><br/> (95% CI 0.27 to 92.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute improvement on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Downgraded two levels for serious imprecision (few events and wide CI).<br/> <sup>g</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>h</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement was defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005522-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tramadol alone compared with NSAIDs for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol alone compared with NSAIDs for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 500 where 0 = no pain) </p> <p>Follow‐up: range 4 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 300.8 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 22 points higher (7 higher to 37 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>952 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 4% absolute worsening (95% CI 1% to 7% worsening),<sup>b</sup> </p> <p>7% relative worsening (95% CI 2% to 12% worsening),<sup>f</sup> </p> <p>SMD 0.21 (95% CI 0.07 to 0.36),</p> <p>NNTB 12 (95% CI 7 to 35)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (8 less to 2 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (95% CI 0.53 to 0.88)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: self‐report questionnaire WOMAC Physical Function (scale 0 to 1700, where 0 = no limitation) </p> <p>Follow‐up: range 4 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was 1019 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was</p> <p>82 higher (32 higher to 131 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>952 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean physical function: 5% absolute worsening (95% CI 2% to 8% worsening),<sup>b</sup> </p> <p>8% relative worsening (95% CI 3% to 13% worsening),<sup>f</sup> </p> <p>SMD 0.23 (95% CI 0.09 to 0.37),</p> <p>NNTB 11 (95% CI 7 to 27)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (7 less to 2 less) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (95% CI 0.59 to 0.88)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse even</b>t </p> <p>Follow‐up: 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>591 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>774 per 1000</b><br/> (609 to 987) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b><br/> (95% CI 1.03 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18% absolute worsening (95% CI 2% more to 40% more),</p> <p>31% relative worsening (95% CI 3% more to 67% more),</p> <p>NNTH 6 (95% CI 3 to 57)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 8 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b><br/> (142 to 309) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.88</b><br/> (95% CI 1.27 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>929 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% absolute worsening (95% CI 3% more to 20% more),</p> <p>88% relative worsening (95% CI 27% more to 176% more), NNTH 10 (95% CI 5 to 33)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 4 weeks to 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b><br/> (0 to 90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b><br/> (95% CI 0.01 to 4.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>).<br/> <sup>h</sup>Downgraded one level for inconsistency.<br/> <sup>i</sup>Downgraded two levels for serious imprecision (few events and wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005522-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tramadol alone compared with other opioids for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol alone compared with other opioids for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> other opioids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Other opioids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 100 mm where 0 = no pain) </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 36 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 3 points lower (9 lower to 3 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>411 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 3% absolute improvement (95% CI 3% worsening to 9% improvement),<sup>b</sup> </p> <p>8% relative improvement (95% CI 8% worsening to 25% improvement),<sup>f</sup> </p> <p>SMD –0.11 (95% CI –0.33 to 0.12)</p> <p>NNTB not applicable<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 more out of 100 (4 less to 11 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> (95% CI 0.83 to 1.48)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function</b> assessed with participants rating their overall assessment of the therapy at end of study as good or better </p> <p>Follow‐up: 2 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>505 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b><br/> (525 to 848) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> (95% CI 1.04 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16% absolute improvement (95% CI 2% more to 34% more),<sup>b</sup> </p> <p>32% relative improvement (95% CI 4% more to 68% more),<sup>f</sup> </p> <p>NNTB: 7 (95% CI 3 to 50)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b><br/> (471 to 612) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (95% CI 0.87 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>e,h,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% absolute worsening (95% CI 7% fewer to 7% more),</p> <p>1% relative worsening (95% CI 13% fewer to 13% more),</p> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>311 per 1000</b><br/> (209 to 464) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.26</b> </p> <p>(95% CI 1.52 to 3.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17% absolute worsening (95% CI 7% more to 33% more),</p> <p>126% relative worsening (95% CI 52% more to 237% more),</p> <p>NNTH 6 (95% CI 3 to 14)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.42</b><br/> (95% CI 0.39 to 141.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>495 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e,j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% absolute worsening (95% CI 0% fewer to 0% fewer),</p> <p>642% relative worsening (95% CI 13% fewer to 41% more),</p> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">mumusculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement was defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results.<br/> <sup>h</sup>Downgraded one level for inconsistency.<br/> <sup>i</sup>Downgraded one level for imprecision (wide CI).<br/> <sup>j</sup>Downgraded two levels for serious imprecision (few events and wide CI). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005522-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol in combination with acetaminophen </p> <p><b>Comparison:</b> NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 10 mm where 0 = no pain) </p> <p>Follow‐up: range 8 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 5.2 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 0.3 points higher (0.4 lower to 0.9 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>226 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 3% absolute worsening (95% CI 9% worsening to 4% improvement),<sup>b</sup> </p> <p>6% relative worsening (95% CI 17% worsening to 8% improvement),<sup>f</sup> </p> <p>SMD 0.12 (–0.16 to 0.39),</p> <p>NNTB not applicable<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (15 less to 6 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> (95% CI 0.68 to 1.13)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: WOMAC Physical Function on a 96‐point scale </p> <p>Follow‐up: 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was 21.40</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was 2 points higher (2 lower to 6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>91 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean physical function: 2% absolute worsening (95% CI 7% worsening to 2% improvement),<sup>b</sup> </p> <p>9% relative worsening (95% CI 28% worsening to 9% improvement),<sup>f</sup> </p> <p>SMD 0.20 (–0.21 to 0.61)</p> <p>NNTB not applicable<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (13 less to 7 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> (95% CI 0.41 to 1.32)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>702 per 1000</b><br/> (522 to 942) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b><br/> (95% CI 0.87 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% absolute worsening (95% CI 8% improvement to 34% worsening),</p> <p>17% relative worsening (95% CI 13% improvement to 57% worsening),</p> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: 3 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference; <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results.<br/> <sup>h</sup>Downgraded one level for imprecision (wide CI).<br/> <sup>i</sup>Downgraded two levels for serious imprecision (no events). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005522-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol in combination with acetaminophen </p> <p><b>Comparison:</b> other opioids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Other opioids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 10 mm where 0 = no pain) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 6.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain of the intervention group was 0.3 points higher (1.8 higher to 1.3 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 3% absolute worsening (95% CI 18% worsening to 13% improvement),<sup>b</sup> </p> <p>5% relative worsening (95% CI 28% worsening to 20% improvement),<sup>f</sup> </p> <p>SMD 0.06 (95% CI –0.31, 0.43),</p> <p>NNTB not applicable<sup>h</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 less out of 100 (16 less to 13 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (95% CI 0.67 to 1.27)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. Corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Downgraded one level for imprecision.<br/> <sup>g</sup>Relative improvement percentage is defined as relative to the control group risk at baseline.<br/> <sup>h</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005522-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005522-sec-0030"></div> <section id="CD005522-sec-0031"> <h3 class="title" id="CD005522-sec-0031">Description of the condition</h3> <p>Osteoarthritis (OA) is a disease characterized by joint pain, stiffness, distortion of joint architecture and functional limitations (<a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>). It accounts for a substantial number of healthcare visits and costs across the world (<a href="./references#CD005522-bbs2-0073" title="MurrayCJ , VosT , LozanoR , NaghaviM , FlaxmanAD , MichaudC , et al. Disability‐adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380:2197‐223. ">Murray 2012</a>). </p> <p>OA, also known as degenerative arthritis, is one of the most frequent disorders and is the most common cause of disability in older adults (<a href="./references#CD005522-bbs2-0072" title="Lesnoff‐CaravagliaG . Health Aspects of Aging: the Experience of Growing Old. Springfield (IL): Charles C Thomas Publisher, 2007. ">Lesnoff‐Caravaglia 2007</a>). It frequently affects the hands, feet, and large weight‐bearing joints such as the hips and the knees (<a href="./references#CD005522-bbs2-0053" title="BuckwalterJA , SaltzmanC , BrownT . The impact of osteoarthritis: implications for research [Review]. Clinical Orthopaedics &amp; Related Research2004;427 Suppl:S6‐S15. ">Buckwalter 2004</a>). The prevalence of OA increases with age, since the ability of the articular cartilage to heal decreases, especially in people aged 50 years and older (<a href="./references#CD005522-bbs2-0054" title="CrossM , SmithE , HoyD , NolteS , AckermanI , FransenM , et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases2014;73:1323‐30. ">Cross 2014</a>; <a href="./references#CD005522-bbs2-0071" title="LawrenceRC , FelsonDT , HelmickCG , ArnoldLM , ChoiH , DeyoRA , et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part II. Arthritis and Rheumatism2008;58(1):26‐35. ">Lawrence 2008</a>). </p> <p>The enzymatic and mechanical breakdown of the matrix of the joint cartilage, and the cartilage's decreased capacity for regeneration are key features of the pathophysiology of OA. In OA, an excessive amount of proteases such as nitric oxide and other inflammatory cytokines are produced by chondrocytes (<a href="./references#CD005522-bbs2-0070" title="LammertE , ZeebM . Metabolism of Human Diseases: Organ Physiology and Pathophysiology. Vienna: Springer, 2014. ">Lammert 2014</a>). These mediators cause cellular injury, inhibit cartilage synthesis and render the chondrocytes susceptible to apoptosis. These inflammatory phenomena, in addition to promoting cartilage damage, stimulate A delta and C fibers in the synovium and surrounding tissues. This neural stimulation leads to peripheral and central sensitization, and chronic pain (<a href="./references#CD005522-bbs2-0069" title="KeanWF , KeanR , BuchananWW . Osteoarthritis: symptoms, signs and source of pain. Inflammopharmacology2004;12(1):3‐31. ">Kean 2004</a>). </p> <p>Pain is the most common symptom of OA, and as pain levels rise, people experience a reduced range of motion and increasing disability (<a href="./references#CD005522-bbs2-0052" title="BjordalJM , LjunggrenAE , KlovningA , SlordalL . Non‐steroidal anti‐inflammatory drugs, including cyclo‐oxygenase‐2 inhibitors, in osteoarthritic knee pain: meta‐analysis of randomised placebo controlled trials. BMJ2004;329(7478):1317. ">Bjordal 2004</a>; <a href="./references#CD005522-bbs2-0056" title="DieppePA , LohmanderLS . Pathogenesis and management of pain in osteoarthritis. Lancet2005;365(9463):965‐73. ">Dieppe 2005</a>). The pain and function limitations substantially reduce the quality of life of people with OA (<a href="./references#CD005522-bbs2-0069" title="KeanWF , KeanR , BuchananWW . Osteoarthritis: symptoms, signs and source of pain. Inflammopharmacology2004;12(1):3‐31. ">Kean 2004</a>). People with OA have a lower quality of life than people with gastrointestinal, cardiovascular or chronic respiratory illnesses (<a href="./references#CD005522-bbs2-0080" title="ReginsterJY . The prevalence and burden of arthritis. Rheumatology (Oxford)2002;41 Supp 1:3‐6. ">Reginster 2002</a>). </p> </section> <section id="CD005522-sec-0032"> <h3 class="title" id="CD005522-sec-0032">Description of the intervention</h3> <p>The treatment goals for OA are to reduce pain and to maintain or improve (or both) functional status and quality of life (<a href="./references#CD005522-bbs2-0049" title="American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis &amp; Rheumatology2000;43:1905‐15. ">ACR 2000</a>; <a href="./references#CD005522-bbs2-0078" title="PendletonA , ArdenN , DougadosM , DohertyM , BannwarthB , BijlsmaJW , et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases2000;59:936‐44. ">Pendleton 2000</a>; <a href="./references#CD005522-bbs2-0085" title="TannenbaumH , PelosoPM , RussellAS , MarlowB . An evidence‐based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: the second Canadian Consensus Conference. Canadian Journal of Clinical Pharmacology2000;7 (Suppl A):4A‐16A. ">Tannenbaum 2000</a>). Several clinical practice guidelines recommend non‐pharmacologic and pharmacologic therapies for the management of OA (<a href="./references#CD005522-bbs2-0064" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care &amp; Research2012;64(4):465‐74. ">Hochberg 2012</a>; <a href="./references#CD005522-bbs2-0066" title="JevsevarDS . Treatment of Osteoarthritis of the Knee: Evidence‐Based Guideline, 2nd Edition. Journal of the American Academy of Orthopaedic Surgeons2013;21:571‐6. ">Jevsevar 2013</a>; <a href="./references#CD005522-bbs2-0082" title="RichmondJ , HunterD , IrrgangJ , JonesMH , Snyder‐MacklerL , VanDurmeD , et al. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. Journal of Bone and Joint Surgery2010;92(4):990‐3. ">Richmond 2010</a>; <a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>). </p> <p>Non‐pharmacologic therapies include weight reduction in obese people, physical therapy (for muscle strengthening), exercise and occupational therapy (e.g. training in the use of devices to assist ambulation) (<a href="./references#CD005522-bbs2-0064" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care &amp; Research2012;64(4):465‐74. ">Hochberg 2012</a>; <a href="./references#CD005522-bbs2-0066" title="JevsevarDS . Treatment of Osteoarthritis of the Knee: Evidence‐Based Guideline, 2nd Edition. Journal of the American Academy of Orthopaedic Surgeons2013;21:571‐6. ">Jevsevar 2013</a>; <a href="./references#CD005522-bbs2-0074" title="National Collaborating Centre for Chronic Conditions. Osteoarthritis National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008. ">NCCCC 2008</a>; <a href="./references#CD005522-bbs2-0082" title="RichmondJ , HunterD , IrrgangJ , JonesMH , Snyder‐MacklerL , VanDurmeD , et al. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. Journal of Bone and Joint Surgery2010;92(4):990‐3. ">Richmond 2010</a>; <a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>). </p> <p>A wide variety of pharmacologic therapies are recommended by the American College of Rheumatology (ACR), the American Academy of Orthopaedic Surgeons (AAOS) and the Osteoarthritis Research Society International (OARSI) (<a href="./references#CD005522-bbs2-0064" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care &amp; Research2012;64(4):465‐74. ">Hochberg 2012</a>; <a href="./references#CD005522-bbs2-0082" title="RichmondJ , HunterD , IrrgangJ , JonesMH , Snyder‐MacklerL , VanDurmeD , et al. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. Journal of Bone and Joint Surgery2010;92(4):990‐3. ">Richmond 2010</a>; <a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>), and are used to treat OA including analgesics such as tramadol (<a href="./references#CD005522-bbs2-0064" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care &amp; Research2012;64(4):465‐74. ">Hochberg 2012</a>; <a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>), non‐steroidal anti‐inflammatory drugs (NSAIDs) (<a href="./references#CD005522-bbs2-0064" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care &amp; Research2012;64(4):465‐74. ">Hochberg 2012</a>; <a href="./references#CD005522-bbs2-0066" title="JevsevarDS . Treatment of Osteoarthritis of the Knee: Evidence‐Based Guideline, 2nd Edition. Journal of the American Academy of Orthopaedic Surgeons2013;21:571‐6. ">Jevsevar 2013</a>; <a href="./references#CD005522-bbs2-0082" title="RichmondJ , HunterD , IrrgangJ , JonesMH , Snyder‐MacklerL , VanDurmeD , et al. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. Journal of Bone and Joint Surgery2010;92(4):990‐3. ">Richmond 2010</a>), and acetaminophen (paracetamol; <a href="./references#CD005522-bbs2-0074" title="National Collaborating Centre for Chronic Conditions. Osteoarthritis National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008. ">NCCCC 2008</a>; <a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>). Acetaminophen, although not associated with an increased risk of gastrointestinal events, is less effective than NSAIDs in reducing pain (<a href="./references#CD005522-bbs2-0074" title="National Collaborating Centre for Chronic Conditions. Osteoarthritis National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008. ">NCCCC 2008</a>; <a href="./references#CD005522-bbs2-0086" title="TowheedT , MaxwellL , JuddM , CattonM , HochbergM , WellsG . Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004257.pub2] ">Towheed 2006</a>). </p> <p>NSAIDs are the cornerstone of pharmacologic therapy for the management of OA, relieving symptoms such as pain (<a href="./references#CD005522-bbs2-0086" title="TowheedT , MaxwellL , JuddM , CattonM , HochbergM , WellsG . Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004257.pub2] ">Towheed 2006</a>). However, their use is associated with gastrointestinal (<a href="./references#CD005522-bbs2-0086" title="TowheedT , MaxwellL , JuddM , CattonM , HochbergM , WellsG . Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004257.pub2] ">Towheed 2006</a>), cardiac (<a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>), and renal problems (<a href="./references#CD005522-bbs2-0074" title="National Collaborating Centre for Chronic Conditions. Osteoarthritis National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008. ">NCCCC 2008</a>), especially in elderly people (<a href="./references#CD005522-bbs2-0077" title="PelletierJP , Martel‐PelletierJ , RannouF , CooperC . Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real‐life setting trials and surveys. Seminars in Arthritis and Rheumatism2016;45:S22‐7. ">Pelletier 2016</a>). There has been ongoing debate that cyclo‐oxygenase‐2 (COX‐2)‐selective NSAIDs have increased cardiac adverse events compared to traditional NSAIDs. However, one non‐inferiority trial published in the <i>New England Journal of Medicine</i> demonstrated that the COX‐2‐selective NSAID, celecoxib, was not inferior to naproxen or ibuprofen in terms of cardiac adverse events (<a href="./references#CD005522-bbs2-0075" title="NissenSE , YeomansND , SolomonDH , LüscherTF , LibbyP , Husni , ME , et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. New England Journal of Medicine2016;375:2519‐29. ">Nissen 2016</a>). </p> <p>Tramadol has been increasingly used for pain relief in people with OA due to having potentially fewer adverse events than with NSAIDs (Cepeda 2006). The ACR and the OARSI recommend tramadol in managing OA pain (<a href="./references#CD005522-bbs2-0064" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care &amp; Research2012;64(4):465‐74. ">Hochberg 2012</a>; <a href="./references#CD005522-bbs2-0089" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16:137‐62. ">Zhang 2008</a>), because in contrast to NSAIDs, it does not produce gastrointestinal bleeding, renal (<a href="./references#CD005522-bbs2-0088" title="ZhangW , JonesA , DohertyM . Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta‐analysis of randomised controlled trials. Annals of the Rheumatic Diseases2004;63(8):901‐7. ">Zhang 2004</a>) or cardiovascular problems (<a href="./references#CD005522-bbs2-0077" title="PelletierJP , Martel‐PelletierJ , RannouF , CooperC . Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real‐life setting trials and surveys. Seminars in Arthritis and Rheumatism2016;45:S22‐7. ">Pelletier 2016</a>). Tramadol is an opioid that acts on the neurotransmission of norepinephrine and serotonin and modifies the transmission of pain impulses (<a href="./references#CD005522-bbs2-0077" title="PelletierJP , Martel‐PelletierJ , RannouF , CooperC . Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real‐life setting trials and surveys. Seminars in Arthritis and Rheumatism2016;45:S22‐7. ">Pelletier 2016</a>). This dual action makes tramadol an attractive option, although dependency is a concern, as with all opiates. </p> <p>Although the analgesic effect of tramadol for acute and neuropathic pain has been established, there are few systematic reviews that evaluate the benefits of tramadol for OA. One systematic review included 11 trials comparing tramadol to placebo and other active controls (Cepeda 2006). Another systematic review included 18 trials comparing opioids including tramadol to placebo (<a href="./references#CD005522-bbs2-0025" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis Cartilage2007;15(8):957‐65. ">Avouac 2007</a>). These systematic reviews demonstrated a significant decrease in pain as well as benefits on physical function. </p> </section> <section id="CD005522-sec-0033"> <h3 class="title" id="CD005522-sec-0033">How the intervention might work</h3> <p>The mechanism for benefits of tramadol in OA is unclear: tramadol lacks peripheral action (i.e<i>.</i> it has no local effects on the joints) and its benefits may decline with chronic use (i.e<i>.</i> development of tolerance), as part of its action is opioid‐related. Nonetheless, the central action of tramadol could be of great benefit as this action could decrease the central neuronal sensitization produced by the persistent nociceptive peripheral input (<a href="./references#CD005522-bbs2-0065" title="JettMF , McGuirkJ , WaligoraD , HunterJC . The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain1997;69(1‐2):161‐9. [MEDLINE: 2002] ">Jett 1997</a>). In addition, tolerance may not be a problem in this people with OA, since systematic reviews have shown that 44% of participants prescribed opioids for chronic non‐cancer pain continued to take opioids for up to 24 months (<a href="./references#CD005522-bbs2-0068" title="KalsoE , EdwardsJE , MooreRA , McQuayHJ . Opioids in chronic non‐cancer pain: systematic review of efficacy and safety. Pain2004;112(3):372‐80. ">Kalso 2004</a>). </p> </section> <section id="CD005522-sec-0034"> <h3 class="title" id="CD005522-sec-0034">Why it is important to do this review</h3> <p>Clinical studies are the best way to determine whether people with OA benefit from using tramadol. This review examined the clinical benefit and harms of tramadol for people with OA. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005522-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005522-sec-0035"></div> <p>To determine the benefits and harms of oral tramadol or tramadol combined with acetaminophen or NSAIDs in people with osteoarthritis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005522-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005522-sec-0036"></div> <section id="CD005522-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005522-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs). Published studies, as well as unpublished studies were eligible. </p> </section> <section id="CD005522-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included studies in adults (i.e<i>.</i>18 years and older) with OA affecting any joints. We included studies that evaluated participants who met one of the following: 1. the ACR clinical criteria for OA; and 2. radiographic evidence of OA. We excluded studies that evaluated other types of arthritis (e.g. rheumatoid arthritis, non‐osteoarthritic joint pain or back pain) or that did not provide data specific to participants with OA. We also excluded studies of tramadol for postoperative pain. </p> </section> <section id="CD005522-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared tramadol (with or without acetaminophen or NSAIDs) with either a placebo or an active treatment. </p> </section> <section id="CD005522-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We included studies that reported the effect of tramadol on pain intensity, physical function and adverse events of tramadol. If a trial reported many time points, we recorded the last time point. </p> <section id="CD005522-sec-0042"> <h5 class="title">Major outcomes</h5> <p>The major outcomes of interest were based on the recommendations for outcomes in OA trials (<a href="./references#CD005522-bbs2-0050" title="AltmanR , BrandtK , HochbergM , MoskowitzR , BellamyN , BlochDA , et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis and Cartilage1996;4(4):217‐43. ">Altman 1996</a>; <a href="./references#CD005522-bbs2-0051" title="BellamyN , KirwanJ , BoersM , BrooksP , StrandV , TugwellP , et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. consensus development at OMERACT III. Journal of Rheumatology1997;24(4):799‐802. ">Bellamy 1997</a>). </p> <p> <ol id="CD005522-list-0001"> <li> <p>Pain.</p> </li> <li> <p>Physical function.</p> </li> <li> <p>Number of participants experiencing any adverse event.</p> </li> <li> <p>Number of participants who withdrew due to adverse events.</p> </li> <li> <p>Number of participants experiencing any serious adverse events.</p> </li> </ol> </p> <p>For trials which assessed results using more than one pain scale, we used the hierarchy of pain‐related outcomes described by <a href="./references#CD005522-bbs2-0067" title="JüniP , ReichenbachS , DieppeP . Osteoarthritis: rational approach to treating the individual. Best Practice &amp; Research. Clinical Rheumatology2006;20(4):721‐40. ">Jüni 2006</a> by extracting data on the pain scale that was highest on this list: </p> <p> <ol id="CD005522-list-0002"> <li> <p>global pain;</p> </li> <li> <p>pain on walking;</p> </li> <li> <p>WOMAC Osteoarthritis Index pain subscore;</p> </li> <li> <p>composite pain scores other than WOMAC;</p> </li> <li> <p>pain on activities other than walking;</p> </li> <li> <p>rest pain or pain during the night;</p> </li> <li> <p>WOMAC Global Algofunctional score;</p> </li> <li> <p>Lequesne Osteoarthritis Index global score;</p> </li> <li> <p>other algofunctional scale;</p> </li> <li> <p>participant's global assessment;</p> </li> <li> <p>physician's global assessment.</p> </li> </ol> </p> <p>For trials which assessed results from more than one physical function scale, we used the same approach as noted above, using the following hierarchy: </p> <p> <ol id="CD005522-list-0003"> <li> <p>global disability score;</p> </li> <li> <p>walking disability;</p> </li> <li> <p>WOMAC Disability subscore;</p> </li> <li> <p>composite disability scores other than WOMAC;</p> </li> <li> <p>disability other than walking;</p> </li> <li> <p>WOMAC Global Scale;</p> </li> <li> <p>Lequesne Osteoarthritis Index global score;</p> </li> <li> <p>other algofunctional scale;</p> </li> <li> <p>participant's global assessment;</p> </li> <li> <p>physician's global assessment.</p> </li> </ol> </p> <p>If a study reported pain or function outcomes at several time points, we extracted the measure at the end of the treatment period. </p> </section> <section id="CD005522-sec-0043"> <h5 class="title">Minor outcomes</h5> <p> <ol id="CD005522-list-0004"> <li> <p>Symptoms of opioid dependence, such as craving or physical withdrawal symptoms.</p> </li> </ol> </p> </section> </section> </section> <section id="CD005522-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005522-sec-0045"> <h4 class="title">Electronic searches</h4> <section id="CD005522-sec-0046"> <h5 class="title">Electronic databases</h5> <p>We searched the following databases:</p> <p> <ol id="CD005522-list-0005"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library; 2018, Issue 1; </p> </li> <li> <p>Ovid MEDLINE 1966 to 1 February 2018;</p> </li> <li> <p>Ovid Embase 1980 to 1 February 2018;</p> </li> <li> <p>LILACS 1982 to 13 August 2015.</p> </li> </ol> </p> </section> <section id="CD005522-sec-0047"> <h5 class="title">Trial registries</h5> <p> <ol id="CD005522-list-0006"> <li> <p>US National Institutes of Health trial registry up to February 2018 (<a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>). </p> </li> <li> <p>World Health Organization trial registry up to February 2018 (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ol> </p> </section> <section id="CD005522-sec-0048"> <h5 class="title">Search terms</h5> <p>For the identification of the studies in MEDLINE, we used the MeSH/EMTREE terms: <a href="./appendices#CD005522-sec-0117">Appendix 1</a>. </p> <p>There were no language restrictions. We translated non‐English language articles and assessed them. Where applicable, we communicated with the authors to obtain information not presented or that was unclear in the manuscripts. </p> <p>For each of the other databases, we based search strategies on the search strategy developed for MEDLINE, but revised appropriately. We searched bibliographies from all retrieved articles for additional studies. </p> </section> </section> </section> <section id="CD005522-sec-0049"> <h3 class="title" id="CD005522-sec-0049">Data collection and analysis</h3> <section id="CD005522-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KTA and either CC or JV) independently screened titles and abstracts for inclusion of all potentially relevant studies identified by the search. We retrieved the full text of all articles in which the record or abstract referred to a trial of tramadol and OA. </p> <p>Two review authors (KTA and either CC or JV) independently screened the full text and identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved disagreements through discussion, and, if required, by a third review author (VW, PT). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="http://prisma-statement.org/PRISMAStatement/Default.aspx" target="_blank">prisma‐statement.org/PRISMAStatement/Default.aspx</a>). </p> </section> <section id="CD005522-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (KTA and either CC or JV) independently extracted information from each study using a standardized, piloted extraction form accompanied by a codebook. We resolved disagreements by discussion, and, if necessary, consulted a third review author (VW). </p> <p>We extracted the following study characteristics.</p> <p> <ol id="CD005522-list-0007"> <li> <p>Methods: study design, total duration of study, study setting and withdrawals.</p> </li> <li> <p>Participants: number, mean age, age range, sex, disease duration, types of joints affected, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: generic and trade name of the intervention, type of control used, dosage, frequency, route of administration and duration of treatment. </p> </li> <li> <p>Outcomes: major and minor outcomes specified and collected, and time points reported.</p> </li> <li> <p>Characteristics of the design of the trial as outlined in the <a href="#CD005522-sec-0052">Assessment of risk of bias in included studies</a> section. </p> </li> <li> <p>Notes: type and source of financial support for trial, and notable declarations of interest of trial authors. </p> </li> </ol> </p> <p>When necessary, we approximated means and measures of dispersion from figures in the reports. For cross‐over trials, we extracted data from the first period only to include in the meta‐analyses. Whenever possible, we used results from an intention‐to‐treat (ITT) analysis. If effect sizes could not be calculated, we contacted the authors for additional data. One review author (TEH) transferred data into Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. </p> </section> <section id="CD005522-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The articles that fulfilled the inclusion criteria underwent quality appraisal. Two review authors (two of the following authors: JB, JV, NA, CC, TEH, LM) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements through discussion, and by a third review author if a consensus could not be reached (KTA, JP, VW, AWSR). </p> <p>We assessed the following risk of bias domains for RCTs:</p> <p> <ol id="CD005522-list-0008"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear risk, and provided a quote from the study report together with a justification for our judgment in the 'Risk of bias' table (see <a href="./references#CD005522-sec-0128" title="">Characteristics of included studies</a> table). Randomization was adequate if it resulted in an unpredictable allocation schedule. Authors had to note that they used a random component (e.g. random assignments generated by a computer). </p> <p>Allocation concealment was adequate if participants and investigators responsible for participant selection were unable to suspect before allocation which treatment was used. Authors had to indicate that they employed central randomization by a third party or used sequentially numbered, opaque, sealed envelopes. </p> <p>Blinding of participants was adequate if experimental and control preparations were explicitly described as indistinguishable or if a study used a double‐dummy technique. Blinding of study personnel was adequate if authors explicitly stated that investigators were blinded. Blinding of outcome assessors was adequate if blinding of participants was considered adequate for self‐reported outcome measures. Blinding of outcome assessors was considered unclear if authors only explicitly stated that participants were blinded for outcome measures that were not self‐reported, as personnel interacting with participants may not have been blinded and may have influenced outcome assessment. </p> <p>Outcome data were considered complete if reasons for any losses to follow‐up, treatment withdrawals or trial group changes were explained by the authors and the reasons for those occurrences were unlikely to be connected with their subsequent outcome. In addition, the occurrence of missing data had to be balanced between intervention and control groups. </p> <p>Outcome reporting was considered complete if the outcomes listed in the protocol matched those reported in the article. Risk of bias for outcome reporting was considered unclear if the protocol was not available. </p> <p>An article was deemed to have demonstrated a low risk of bias for 'other biases' if no other internal biases were identified. Analyses were considered adequate if all randomized participants were included in the analysis according to the ITT principle. </p> <p>For the cross‐over RCTs, we answered the following questions to assess the risk of bias (see other bias section in the <a href="#CD005522-sec-0052">Assessment of risk of bias in included studies</a>). </p> <p> <ol id="CD005522-list-0009"> <li> <p>Was use of a cross‐over design appropriate?</p> </li> <li> <p>Was it clear that the order of receiving treatments was randomized?</p> </li> <li> <p>Could it be assumed that the trial was not biased from carry‐over effects?</p> </li> <li> <p>Were unbiased data available?</p> </li> </ol> </p> </section> <section id="CD005522-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <section id="CD005522-sec-0054"> <h5 class="title">Major outcomes</h5> <section id="CD005522-sec-0055"> <h6 class="title">1. Pain</h6> <p>We extracted the mean and standard deviation (SD) of pain in each study group after treatment, and calculated the mean differences (MD). In cases where the studies reported the difference in pain with no measure of dispersion, we estimated the standard error (SE) of the difference from the P value and the number of participants in each group, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). To pool the data, we chose generic inverse variance fixed‐effect models a priori. We also used random‐effects models to verify if the two models gave consistent results. We then transformed the MD between groups and the SE into a standardized mean difference (SMD) and the SE of that SMD. We calculated the corresponding number needed to treat for an additional beneficial outcome (NNTB) and the mean percentage of participants who acquired a minimally clinically important difference (MCID) using the Wells calculator (available at the CMSG Editorial office <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>). The Wells calculator obtains the NNTB by taking the reciprocal of the net proportion of the population benefiting from an intervention (1/P(b)). The net proportion benefiting is dependent on the proportions benefiting in control and treatment groups and the proportion worsening in control and treatment groups which are in turn derived from the normal distribution of the difference between the minimally important difference and the effect size of a trial (SMD) (<a href="./references#CD005522-bbs2-0076" title="NormanGR , SridharFG , GuyattGH , WalterSD . Relation of distribution‐and anchor‐based approaches in interpretation of changes in health‐related quality of life. Medical Care2001;39(10):1039‐47. ">Norman 2001</a>). </p> <p>We also calculated the risk ratio (RR) by dividing the percentage of participants who improved in the treatment group by the mean percentage of participants who improved in the control group (corresponding risk/assumed risk) and 95% confidence intervals (CI). We added information on the NNTB, the mean percentage of participants who acquire an MCID and the RR in the footnotes of the 'Summary of findings' tables. The MCID was 20% of a pain scale (<a href="./references#CD005522-bbs2-0079" title="PhamT , Van DerHeijdeD , LassereM , AltmanRD , AndersonJJ , BellamyN , et al. Outcome variables for osteoarthritis clinical trials: the OMERACT‐OARSI set of responder criteria. Journal of Rheumatology2003;30(7):1648‐54. ">Pham 2003</a>; <a href="./references#CD005522-bbs2-0087" title="TubachF , RavaudP , BaronG , FalissardB , LogeartI , BellamyN , et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Annals of Rheumatic Diseases2005;64(1):29‐33. ">Tubach 2005</a>). It is important to note that when results are not statistically significant but CIs are wide, results may be explained by uncertainty. Thus, it does not preclude the intervention from having an effect if more research was conducted. </p> </section> <section id="CD005522-sec-0056"> <h6 class="title">2. Physical function</h6> <p>We extracted the mean and SD in each study arm after treatment and calculated the MDs and 95% CI. If studies reported the MD in physical function between treatments without a measure of dispersion, we estimated the SE of the difference from the P value and the number of participants in each group, as described in the Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a><i>)</i>. To pool the data, we chose generic inverse variance fixed‐effect models a priori. We also used random‐effects models to verify if the two models gave consistent results. We then transformed the MD between groups and the SE into a SMD and the SE of that SMD. We calculated the corresponding NNTB and the mean percentage of participants who acquired an MCID using the Wells calculator (available at the CMSG Editorial office <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>). We also calculated the RR by dividing the percentage of participants who improved in the treatment group by the mean percentage of participants who improved in the control group (corresponding risk/assumed risk). We added information on the NNTB, the mean percentage of participants who acquired an MCID and the RR in the footnotes of the 'Summary of findings' tables. The MCID was 20% for physical function (<a href="./references#CD005522-bbs2-0079" title="PhamT , Van DerHeijdeD , LassereM , AltmanRD , AndersonJJ , BellamyN , et al. Outcome variables for osteoarthritis clinical trials: the OMERACT‐OARSI set of responder criteria. Journal of Rheumatology2003;30(7):1648‐54. ">Pham 2003</a>; <a href="./references#CD005522-bbs2-0087" title="TubachF , RavaudP , BaronG , FalissardB , LogeartI , BellamyN , et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Annals of Rheumatic Diseases2005;64(1):29‐33. ">Tubach 2005</a>). </p> </section> <section id="CD005522-sec-0057"> <h6 class="title">3. Harms of tramadol</h6> <p>To evaluate the harms of tramadol, we extracted the proportion of participants who developed any adverse events, withdrawals due to adverse events and serious adverse events. We relied upon the definitions used by authors of the trials. We calculated the RR and corresponding number needed to treat for an additional harmful effect (NNTH), with 95% CIs. </p> </section> </section> <section id="CD005522-sec-0058"> <h5 class="title">Minor outcomes</h5> <section id="CD005522-sec-0059"> <h6 class="title">1. Withdrawal symptoms and propensity for abuse</h6> <p>To evaluate the data pertaining to withdrawal symptoms, we extracted the proportion of participants who developed these symptoms and the proportion of participants who developed a propensity for abuse. We calculated the RR and corresponding NNTH, with 95% CIs. </p> </section> </section> </section> <section id="CD005522-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>Where multiple trial arms were reported in a single trial, we included only the relevant arms. </p> </section> <section id="CD005522-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as an abstract only or when data were not available for all participants). </p> <p>For dichotomous outcomes, we calculated the withdrawal rate using the number of participants randomized in the group as the denominator. </p> <p>For continuous outcomes, we calculated the MD or SMD based on the number of participants analyzed at that time point. If the number of participants analyzed was not presented for each time point, we used the number of randomized participants in each group at baseline. </p> <p>Where possible, we computed missing SDs from other statistics such as SEs, CIs or P values, according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 7; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD005522-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>To evaluate statistical heterogeneity, we performed a visual inspection of the forest plot to assess differences in results between the studies when there was a sufficient number of trials. We also used the I² and Chi² statistical tests (<a href="./references#CD005522-bbs2-0062" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 1811] ">Higgins 2003</a>). We assessed clinical heterogeneity in terms of participants, interventions, outcomes, study characteristics and setting of the included trials. As recommended in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), the interpretation of an I² value of 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity and 75% to 100% represents considerable heterogeneity. The Chi² test was interpreted where a P ≤ 0.05 indicated evidence of statistical heterogeneity. </p> </section> <section id="CD005522-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>We created and examined funnel plots to explore possible small‐study biases when there was a sufficient number of trials. To assess outcome reporting bias, we verified trial protocols against published reports. </p> </section> <section id="CD005522-sec-0064"> <h4 class="title">Data synthesis</h4> <p>We summarized continuous outcomes using SMDs and expressed dichotomous outcomes as RRs. We used standard inverse‐variance fixed‐effect meta‐analyses to combine the trials (<a href="./references#CD005522-bbs2-0055" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We also used random‐effects models to verify if the two models gave consistent results.SMD were also translated into MDs on commonly used scales. </p> <section id="CD005522-sec-0065"> <h5 class="title">GRADE and 'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables for the major outcomes<i>.</i> We added the absolute and relative percent change in the 'Summary of findings' tables. </p> <p>Two review authors (of: JB, JV, NA, CC, TEH) independently assessed the quality of the evidence. We used the five GRADE considerations (unclear risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the studies which contributed data to the meta‐analyses for the prespecified outcomes. We reported the quality of evidence as high, moderate, low or very low. Low quality means our confidence in the effect estimate was limited, whereas the moderate quality means we were moderately confident in the effect estimate. We considered the following criteria for upgrading the quality of evidence, if appropriate: large effect, dose‐response gradient and plausible confounding effect. We used methods and recommendations described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>; <a href="./references#CD005522-bbs2-0084" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). We used GRADEpro software to prepare the 'Summary of findings' tables (<a href="./references#CD005522-bbs2-0059" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes and made comments to aid the reader's understanding of the review where necessary. We resolved disagreements by consensus, and by a third review author if a consensus could not be reached (KTA, JP, VW, AWSR). </p> </section> </section> <section id="CD005522-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analyzed placebo‐controlled studies and active‐controlled studies separately. We analyzed studies that evaluated tramadol alone or tramadol plus acetaminophen or NSAIDs together, as the results of these trials were similar. </p> <section id="CD005522-sec-0067"> <h5 class="title">Interpreting results and reaching conclusions</h5> <p>We followed the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for interpreting results and distinguished a lack of evidence of effect from a lack of effect (<a href="./references#CD005522-bbs2-0084" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005522-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005522-sec-0068"></div> <section id="CD005522-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD005522-sec-0070"> <h4 class="title">Results of the search</h4> <p>In the updated search conducted in February 2018, we identified 347 records through database searching and 37 records through other sources. After eliminating duplicates, we screened 372 records. We excluded 332 records after reviewing their titles and abstracts, leaving 40 full‐text articles which were assessed for eligibility. Eighteen articles were then excluded after reviewing the full text of these articles: three articles were not relevant to chronic management of knee or hip OA, or OA was not evaluated separately in these articles; two articles did not evaluate tramadol and 13 were not RCTs. We included 22 articles in this review and we excluded 11 of these from the meta‐analyses due to missing data. Three of these articles were secondary publications of another trial (<a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>), with no new outcomes of interest (Florete 2008; Vorsanger 2007), and eight which were reports of protocols for which the full data could not be accessed (see <a href="./appendices#CD005522-sec-0118">Appendix 2</a>). Thus, we included 11 articles in this review, which represented 11 RCTs in this updated search. When combined with the RCTs from the search of the earlier version of this systematic review (11 RCTs), it amounted to 22 RCTs (see PRISMA flow diagram in <a href="#CD005522-fig-0001">Figure 1</a>). However, one of these could not be included in the meta‐analyses because it was a cross‐over trial in which results were presented for all treatment periods combined for all outcomes of interest (<a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). These data were presented separately in the results. </p> <div class="figure" id="CD005522-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. OA: osteoarthritis; RCT: randomized controlled trial." data-id="CD005522-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. OA: osteoarthritis; RCT: randomized controlled trial.</p> </div> </div> </div> </section> <section id="CD005522-sec-0071"> <h4 class="title">Included studies</h4> <p>We included 22 RCTs in the present update (11 more than the previous review) of which 21 RCTs were included in meta‐analyses for 3871 participants who were randomized to tramadol alone or tramadol in combination with another analgesic and 2625 participants who were randomized to placebo or active‐control (see <a href="./references#CD005522-sec-0128" title="">Characteristics of included studies</a> table for further details). All studies were funded by the pharmaceutical industry with the exception of two (<a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>). All RCTs were parallel in design, with the exceptions of four studies, which used a cross‐over design (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). One study provided no data on the benefits of tramadol, as the aim of the study was to evaluate the tramadol‐sparing effect of naproxen (<a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>). One cross‐over study provided data on benefits but this evidence could not be pooled with other studies as results were presented for all treatment periods combined (<a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>). These two studies were included since they provided some data for the evaluation of harms. Only two trials were registered in the ClinicalTrials.gov register (<a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>), although 10 trials included in the meta‐analyses were published after 2005. </p> <p>Thirteen RCTs used placebo controls (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>; <a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). In 11 studies, the active control was either acetaminophen 1500 mg/day (<a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>); NSAIDs (i.e. diclofenac 86.9 mg/day (<a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>), diclofenac 75 mg/day to 100 mg/day (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>), celecoxib 200 mg/day (<a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>), loxoprofen 180 mg/day (<a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>), meloxicam 7.5 mg or 15 mg or aceclofenac 100 mg (<a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>), acetaminophen, indomethacin, brufen, diclofenac, feldene or mefenamate (<a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>) (since this group was not randomized, it was excluded from the analyses) and naproxen 500 mg/day (<a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>)); or other opioids (i.e. transdermal fentanyl 25 μg/day to 50 μg/day (<a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>), dihydrocodeine 120 mg/day (<a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>), dextropropoxyphene 300 mg/day (<a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>), transdermal buprenorphine 5 μg/day to 20 μg/day (<a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>), and pentazocine 150 mg/day (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>)). Two studies used both placebo and active controls (<a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>). Seventeen studies evaluated tramadol alone (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>; <a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>), and five evaluated tramadol plus acetaminophen (<a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>). </p> <p>The doses of tramadol used in the studies were variable, ranging from 37.5 mg to 400 mg daily. We assessed whether there were differences in the results depending on dose. Since the results were similar, we decided to pool the doses. All studies evaluated people with symptomatic OA of the hip or knee (or both) with 13 studies including participants with knee or hip OA and nine studies with knee OA. All studies included people aged 18 years or older, and 12 studies included people aged 35 years or older. Participants were predominantly women, with a mean age of 63 years. Most studies included participants with moderate to severe pain, with several studies defining this as a visual analog scale (VAS) score of at least 40 mm on a 100 mm scale. The mean number of participants in the tramadol group was 176 (range 10 to 815) and in the control groups was 119 (range 10 to 405). The mean length of the studies was 54 days (range 3 days to 91 days). Nine studies were 12 weeks long and four studies were eight weeks long; the remainder of the studies varied in duration. </p> <section id="CD005522-sec-0072"> <h5 class="title">Assessed primary and secondary outcomes</h5> <section id="CD005522-sec-0073"> <h6 class="title">Major outcomes: pain and physical function</h6> <p>A total of 19 RCTs reported major outcomes, such as pain or physical function (or both) outcome of interest (i.e. RCTs with outcomes rated the highest on the hierarchy of outcomes described in the methods) (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>; <a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). All these RCTs reported the effect of tramadol on pain. Eleven RCTs reported the effect of tramadol on physical function (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>). </p> <p>Six RCTs evaluated pain using the WOMAC Pain subscale (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>). Eight RCTs evaluated pain intensity using a VAS (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>). One trial evaluated pain intensity during movement using a 4‐point Likert scale (<a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>), and the other trials evaluated pain intensity using a 4‐point Likert scale (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>), a numerical rating scale (<a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>), and the Box scale 11 (<a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>). </p> <p>Ten RCTs evaluated physical function using the WOMAC Physical Function subscale (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). One trial used the WOMAC Total score (<a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>). One trial used an overall assessment of the therapy scored on a 5‐point Likert scale that was then transformed into a dichotomous scale (<a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>). We used this overall assessment as a proxy for physical function. </p> </section> <section id="CD005522-sec-0074"> <h6 class="title">Major outcomes: harms</h6> <p>All RCTs assessed harms outcomes, such as any adverse events, withdrawal due to adverse events, and serious adverse events. These included 10 trials assessing the number of participants with any adverse events, 16 trials assessing the number of participants who withdrew because of adverse events and 14 trials assessing the number of participants with serious adverse events. </p> </section> <section id="CD005522-sec-0075"> <h6 class="title">Minor outcomes: withdrawal symptoms and propensity for abuse</h6> <p>Three trials reported withdrawal symptoms or propensity for abuse, or both (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>). Another trial reported that there was no evidence of abuse but did not mention if it was assessed (<a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>). </p> </section> </section> </section> <section id="CD005522-sec-0076"> <h4 class="title">Excluded studies</h4> <p>In the full‐text screening, we excluded 18 full‐text articles in this update. Three articles did not present data for knee or hip OA, two articles did not evaluate tramadol and 13 did not report RCTs. A list of some of the excluded studies from both abstract/title and full‐text screening phases is shown in <a href="./references#CD005522-sec-0129" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD005522-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD005522-fig-0002">Figure 2</a> shows the assessment of risk of bias for each included study and <a href="#CD005522-fig-0003">Figure 3</a> shows a summary of the risk of bias across the different types of bias. </p> <div class="figure" id="CD005522-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD005522-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD005522-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD005522-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD005522-sec-0078"> <h4 class="title">Allocation</h4> <section id="CD005522-sec-0079"> <h5 class="title">Random sequence generation</h5> <p>Thirteen trials reported adequate sequence generation, eight trials reported unclear sequence generation (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>), and one trial reported inadequate sequence generation (<a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). </p> <p>Four trials reported adequate allocation concealment (<a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>), while most others had unclear allocation concealment, except for two trials that had inadequate allocation concealment (<a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). </p> </section> </section> <section id="CD005522-sec-0080"> <h4 class="title">Blinding</h4> <p>All but five trials were at low risk of bias for blinding of participants and all but six had a low risk of bias for blinding of outcome measures. However, most trials had unclear or high risk of bias for blinding of personnel while seven trials showed a low risk of bias. All but four trials were described as double‐blind (<a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). Twelve trials reported the use of indistinguishable interventions to blind participants (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>), whereas four trials used double‐dummy techniques (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>). Though described as double‐blind, the authors of two trials did not describe blinding procedures (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). </p> </section> <section id="CD005522-sec-0081"> <h4 class="title">Incomplete outcome data</h4> <p>Ten trials were at a low risk of bias for incomplete outcome data for pain and physical function (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>; <a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>), two were unclear (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>), and the reminder showed a high risk of bias. Twelve trials were at a low risk of bias for incomplete outcome data for adverse events, three were unclear (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>), and the reminder showed a high risk of bias. Eleven trials described their benefits analysis to be according to the ITT principle (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>), but some of these trials provided numbers for final analyses that were different from the numbers of randomized participants for pain and physical function outcomes. Among studies which did not employ the ITT principle and for which benefits data were usable for the purposes of this review update, exclusion of participants from the analysis of benefits outcomes ranged from 10% to 45% in the experimental groups and from 6% to 60% in the control groups. </p> </section> <section id="CD005522-sec-0082"> <h4 class="title">Selective reporting</h4> <p>All outcomes mentioned in trials' methods were reported in most studies. However, we could only find the protocol of two trials (<a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>). Most studies reported adverse events that were the most common. </p> </section> <section id="CD005522-sec-0083"> <h4 class="title">Other potential sources of bias</h4> <p>Some of the cross‐over trials did not appear to use adequate methods (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>). </p> </section> </section> <section id="CD005522-sec-0084"> <h3 class="title" id="CD005522-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD005522-tbl-0001"><b>Summary of findings for the main comparison</b> Tramadol alone compared with placebo for osteoarthritis</a>; <a href="./full#CD005522-tbl-0002"><b>Summary of findings 2</b> Tramadol in combination with acetaminophen compared with placebo for osteoarthritis</a>; <a href="./full#CD005522-tbl-0003"><b>Summary of findings 3</b> Tramadol alone compared with acetaminophen for osteoarthritis</a>; <a href="./full#CD005522-tbl-0004"><b>Summary of findings 4</b> Tramadol alone compared with NSAIDs for osteoarthritis</a>; <a href="./full#CD005522-tbl-0005"><b>Summary of findings 5</b> Tramadol alone compared with other opioids for osteoarthritis</a>; <a href="./full#CD005522-tbl-0006"><b>Summary of findings 6</b> Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis</a>; <a href="./full#CD005522-tbl-0007"><b>Summary of findings 7</b> Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis</a> </p> <section id="CD005522-sec-0085"> <h4 class="title">Major outcomes</h4> <section id="CD005522-sec-0086"> <h5 class="title">Benefits</h5> <section id="CD005522-sec-0087"> <h6 class="title">Pain</h6> <section id="CD005522-sec-0088"> <p><b>Placebo‐controlled studies</b></p> <p>Eight trials including 2647 participants in the tramadol alone groups and 1325 participants in the placebo control groups contributed to the analysis of knee or hip pain. Two trials including 350 participants in the combined tramadol/acetaminophen groups and 264 in the placebo control groups contributed to the analysis of knee or hip pain. </p> <p>We found moderate quality evidence that tramadol alone had a small and probably not clinically important pain reduction compared to placebo control interventions (SMD –0.25, 95% CI –0.32 to –0.18; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). Fifteen out of 100 people in the tramadol group improved by 20% (which corresponded to a clinically important difference in pain) compared to 10/100 in the placebo group (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). On a scale of 0 to 100, people in the tramadol group had a 4‐point reduction in pain (95% CI 3 to 5; 8 studies, 3972 participants). This translated into an NNTB of 13 (95% CI 10 to 18). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 0% indicated a low degree of statistical heterogeneity. A visual inspection of the funnel plot suggested symmetry (see <a href="#CD005522-fig-0004">Figure 4</a>). Applying the GRADE criteria to value the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD005522-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Tramadol versus placebo, outcome: 1.1 Pain." data-id="CD005522-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Tramadol versus placebo, outcome: 1.1 Pain.</p> </div> </div> </div> <p>One cross‐over study, which was not included in the meta‐analyses, showed that WOMAC Osteoarthritis Index subscale scores for pain were statistically significantly better with tramadol compared to placebo (189.0 (SD 105.0) with tramadol versus 230.0 (SD 115.4) with placebo; P = 0.0001), but these differences were probably not clinically important (<a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). The study also measured pain intensity using an ordinal scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = excruciating) and a VAS scale (from 0 mm to 100 mm). Tramadol had statistically significantly lower VAS pain intensity scores compared with placebo (37.4 (SD 23.9) with tramadol versus 45.1 (SD 24.3) with placebo; P = 0.0009), but these differences were probably not clinically important. </p> <p>We found moderate quality evidence that tramadol in combination with acetaminophen had a small but probably not clinically important pain reduction compared to placebo control interventions (SMD –0.28, 95% CI –0.45 to –0.12; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). Twelve out of 100 people improved in a clinically important way in the tramadol in combination with acetaminophen group compared to 7/100 in the placebo group (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). On a scale of 0 to 100, people in the tramadol in combination with acetaminophen group had a 4‐point reduction in pain (95% CI 2 to 6; 2 studies, 614 participants). This translated into an NNTB of 14 (95% CI 9 to 33). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 0% indicated a low degree of heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005522-sec-0089"> <p><b>Active‐controlled studies</b></p> <p>Eleven trials including 1017 participants in experimental groups and 668 participants in active control groups (which included acetaminophen, NSAIDs and opioids as active controls) contributed to the analyses of knee or hip pain. </p> <p>Due to very low quality evidence, we were uncertain whether tramadol alone reduced pain compared to acetaminophen (SMD 0.13, 95% CI –0.80 to 1.06; <a href="./full#CD005522-tbl-0003">summary of findings Table 3</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>). Seven out of 100 people improved in a clinically important way with tramadol compared to 9/100 people in the acetaminophen group (see <a href="./full#CD005522-tbl-0003">summary of findings Table 3</a>). Compared to the acetaminophen group, people in the tramadol group had a 2‐point increase in pain (95% CI –12 to 16 on a scale of 0 to 100; 1 study, 20 participants). Applying the GRADE criteria to the overall quality of the evidence, we downgraded three times due to unclear risk of bias and the serious imprecision in the included trials (see <a href="./full#CD005522-tbl-0003">summary of findings Table 3</a>). </p> <p>We found moderate quality evidence that tramadol alone was less effective in pain reduction compared to NSAIDs (SMD 0.21, 95% CI 0.07 to 0.36; <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>). Twelve out of 100 people improved in a clinically important way in the tramadol group compared to 17/100 in the NSAID group (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). Compared to NSAIDs, people in the tramadol group had a 4‐point worsening in pain on a scale of 0 to 100 (95% CI 1 to 7; 3 studies, 952 participants). This translated into an NNTB of 12 (95% CI 7 to 35). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 23% indicated a low degree of statistical heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). </p> <p>We found moderate quality evidence that tramadol alone did not lead to pain reduction compared to other opioids (SMD –0.11, 95% CI –0.33 to 0.12; 4 studies, 411 participants; <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>; <a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). Twenty‐six out of 100 people improved in a clinically important way in the tramadol group compared to 23/100 people in the other opioid group (see <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 0% indicated a low degree of statistical heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>). </p> <p>We found moderate quality evidence that tramadol in combination with acetaminophen did not lead to pain reduction compared to NSAIDs (SMD 0.12 95% CI –0.16 to 0.39; <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>). Forty‐two out of 100 people improved in a clinically important way in the tramadol in combination with acetaminophen group compared to 47/100 people in the NSAIDs group (2 studies, 226 participants; <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 35% indicated a low degree of statistical heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>). </p> <p>We found low quality evidence that tramadol in combination with acetaminophen did not lead to pain reduction compared to other opioids (SMD 0.06, 95% CI –0.31 to 0.43; 2 studies, 226 participants; <a href="./full#CD005522-tbl-0007">summary of findings Table 7</a>; <a href="./references#CD005522-bbs2-0010" title="FujiiT , TakanaK , OritaS , InoueG , OchiaiN , KuniyoshiK , et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial. Yonsei Medical Journal2014;55(5):1379‐85. ">Fujii 2014</a>). Thirty out of 100 people improved in a clinically important way in the tramadol in combination with acetaminophen group compared to 32/100 people in the other opioids group (1 study, 130 participants; see <a href="./full#CD005522-tbl-0007">summary of findings Table 7</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias in the included trials and the imprecision between trials (see <a href="./full#CD005522-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> <section id="CD005522-sec-0090"> <h6 class="title">Physical function</h6> <section id="CD005522-sec-0091"> <p><b>Placebo‐controlled trials</b></p> <p>Five studies including 1789 participants in the tramadol alone groups and 761 participants in the placebo control groups contributed to the analysis of physical function (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>). Two studies including 350 participants in the tramadol in combination with acetaminophen groups and 264 participants in the placebo control groups contributed to the analysis of physical function (<a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>). </p> <p>We found moderate quality evidence that tramadol alone had a small but probably not clinically important benefit in physical function compared to placebo (SMD –0.20, 95% CI –0.29 to –0.12; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). Twenty‐one percent of people in the tramadol group improved by 20%, which corresponded to a clinically important difference in physical function, and 16% of people improved in a clinically important way in the placebo group (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). On a scale of 0 to 100, people in the tramadol group had a 4‐point improvement in physical function (95% CI 2 to 6; 5 studies, 2550 participants). This translated into an NNTB of 13 (95% CI 9 to 21). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 54% indicated a moderate degree of statistical heterogeneity. One trial was responsible for the statistical heterogeneity (<a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>). The trial had three intervention groups with different doses of tramadol (100 mg, 200 mg and 300 mg) and had both a placebo and active control group. The trial indicated no statistically significant or clinically important difference in physical function (SMD –0.02, 95% CI –0.18 to 0.14). Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>One study, which was not included in the meta‐analyses, found that WOMAC Osteoarthritis Index subscale scores for physical function were statistically significantly better with tramadol alone compared to placebo, but these differences were probably not clinically important (632.4 (SD 361.3) with tramadol alone versus 727.4 (SD 383.4) with placebo; P = 0.0205; <a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). </p> <p>We found moderate quality evidence that tramadol in combination with acetaminophen had a small but probably not clinically important benefit in physical function compared to placebo (SMD –0.27, 95% CI –0.43 to –0.11; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). Fifteen percent of people improved in a clinically important way in the tramadol in combination with acetaminophen group compared to 10% in the placebo group (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a> for the main comparison). On a scale of 0 to 100, people in the tramadol in combination with acetaminophen group had a 4‐point improvement in physical function (95% CI 2 to 7; 2 studies, 614 participants). This translated into an NNTB of 12 (95% CI 8 to 30). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). An I<sup>2</sup> statistic of 0% indicated low degree of heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias in the included trials (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005522-sec-0092"> <p><b>Active‐controlled trials</b></p> <p>Five studies including 769 participants in experimental groups and 410 participants in active control groups (which included NSAIDs and other opioids) contributed to the analysis of physical function. </p> <p>We found low quality evidence that tramadol alone had a small but probably not clinically important worsening in physical function compared to NSAIDs (SMD 0.23, 95% CI 0.09 to 0.37; <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>). Twelve out of 100 people improved in a clinically important way with tramadol alone compared to 17/100 people in the NSAIDs group (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). On a scale of 0 to 100, people in the tramadol group had a 5‐point worsening in physical function compared to the NSAIDs group (95% CI 2 to 8; 3 studies, 952 participants). This translated into an NNTB of 11 (95% CI 7 to 27). There was no substantial clinical heterogeneity of the participants (i.e. there were no important differences in sample, intervention or control group characteristics). However, an I<sup>2</sup> statistic of 70% indicated a high degree of statistical heterogeneity. One trial was responsible for most of the statistical heterogeneity (<a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>). This trial has a small sample size (54 participants) and included participants as young as 18 years old, contrary to most studies. It employed a cross‐over design and only data obtained during the first four weeks of the trial were analyzed. The SMD, though not statistically significant, indicated an improvement in physical function compared to NSAIDs, contrary to the other trials comparing tramadol alone and NSAIDs (SMD –0.38, 95% CI –0.92 to 0.16). Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and inconsistency (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). </p> <p>We found moderate quality evidence that tramadol alone had a small but probably not clinically important benefit in overall assessment at end of therapy compared to other opioids (RR 1.32, 95% CI 1.04 to 1.68; 1 study, 190 participants; <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>). According to the only study in this analysis, 67/100 people defined their overall assessment at end of therapy as good or better in the tramadol group compared to 51/100 people in the opioids group. This translated into an NNTB of 7 (95% CI 3 to 50). Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias (see <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>). </p> <p>We found low quality evidence that tramadol in combination with acetaminophen did not improve physical function compared to NSAIDs (SMD 0.20, 95% CI –0.21 to 0.61; 1 study, 91 participants; <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>). Seventeen out of 100 people improved in a clinically important way in the tramadol in combination with acetaminophen group compared to 22/100 people in the NSAIDs group (see <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and imprecision (see <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>). </p> </section> </section> </section> <section id="CD005522-sec-0093"> <h5 class="title">Harms</h5> <section id="CD005522-sec-0094"> <h6 class="title">Any adverse events</h6> <section id="CD005522-sec-0095"> <p><b>Placebo‐controlled trials</b></p> <p>Four trials including 1366 participants in the tramadol alone groups and 673 participants in the placebo control groups reported the number of participants presenting with any adverse events (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>). One trial including 197 participants in the combined tramadol/acetaminophen groups and 111 participants in the placebo control group reported the number of participants presenting with any adverse events (<a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>). There were 1424 people with adverse events in these five trials. Tramadol may cause adverse effects such as nausea, vomiting, dizziness, constipation, tiredness, headache, sweating and abdominal pain. </p> <p>We found moderate quality evidence that there was a greater risk of developing any adverse events with tramadol alone compared to placebo (RR 1.34, 95% CI 1.24 to 1.46; 4 studies, 2039 participants; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). Sixty‐six out of 100 people may have developed adverse effects when taking tramadol alone compared to 49/100 people when taking placebo, which corresponded to 17 more people out of 100 who develop adverse events. The NNTH to cause one additional participant to experience an adverse event was 6 (95% CI 5 to 9). An I<sup>2</sup> statistic of 62% indicated a high degree of heterogeneity. One trial was responsible for most of the statistical heterogeneity (<a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>). This could be explained by the duration of the trial, which was two weeks as compared to the 12‐week duration for the other trials, as well as the population, which was exclusively white as compared to the slightly more diverse population of the other studies. It had a higher RR than the other studies (RR 2.33, 95% CI 1.53 to 3.55). Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In one study which was not included in the meta‐analyses, 94 (79.8%) participants reported adverse events during tramadol treatment while 88 (65.9%) participants reported adverse events during placebo treatment (<a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). The difference in the overall number of adverse events between treatment groups was not clinically significant (P = 0.0833). </p> <p>We found moderate quality evidence that there was a greater risk of developing any adverse events with tramadol in combination with acetaminophen compared to placebo (RR 1.91, 95% CI 1.32 to 2.76; 1 study, 308 participants; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). Forty‐five out of 100 people may have developed adverse effects when taking tramadol in combination with acetaminophen compared to 23/100 people when taking a placebo, which corresponded to 22 more people out of 100 who developed adverse events. The NNTH to cause one additional participant to experience an adverse event was 5 (95% CI 3 to 14; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005522-sec-0096"> <p><b>Active‐controlled trials</b></p> <p>Five trials reported the number of participants presenting with any adverse event including 326 participants in experimental groups (tramadol alone and tramadol in combination with acetaminophen) and 331 participants in active control groups (including NSAIDs and opioids). There were 403 people with adverse events in these five trials. </p> <p>We found moderate quality evidence that there was a greater risk of developing any adverse events with tramadol alone compared to NSAIDs (RR 1.31, 95% CI 1.03 to 1.67; 1 study, 128 participants; see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>). Seventy‐seven out of 100 people may have developed adverse effects when taking tramadol alone compared to 59 out of 100 people when taking NSAIDs, which corresponded to 18 more people out of 100 who develop adverse events. The NNTH to cause one additional participant to experience an adverse event was 6 (95% CI 3 to 57). Applying the GRADE criteria to the overall quality of the evidence, we downgraded once due to unclear risk of bias (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). </p> <p>Due to very low quality evidence, we were uncertain whether tramadol alone had an increased risk of adverse events compared to other opioids (RR 0.99, 95% CI 0.87 to 1.13; 3 studies, 438 participants; <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>; <a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>). An I<sup>2</sup> statistic of 90% indicated a high degree of heterogeneity for the trials comparing tramadol alone to other opioids. One trial was responsible for some of the statistical heterogeneity (<a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>). This trial indicated that tramadol increased the risk of overall adverse events compared to other opioids, contrary to the findings of the other trials. This could be explained by the high dose of tramadol given to the treatment group (tramadol 100 mg three times daily). Applying the GRADE criteria to the overall quality of the evidence, we downgraded three times due to unclear risk of bias, inconsistency and imprecision (see <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>). </p> <p>We found low quality evidence that in one trial comparing tramadol in combination with acetaminophen to NSAIDs, there was no increase in risk of developing any adverse events (RR 1.17 95% CI 0.87 to 1.57; 1 study, 91 participants; <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>; <a href="./references#CD005522-bbs2-0016" title="ParkK‐S , ChoiJ‐J , KimW‐U , MinJ‐K , ParkS‐H , ChoC‐S . The efficacy of tramadol/acetaminophen combination tablets (Ultracet©) as add‐on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti‐inflammatory drug (NSAID). Clinical Rheumatology2012;31:317‐23. ">Park 2012</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and imprecision (see <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>). </p> </section> </section> <section id="CD005522-sec-0097"> <h6 class="title">Withdrawals due to adverse events</h6> <section id="CD005522-sec-0098"> <p><b>Placebo‐controlled trials</b></p> <p>Nine trials with 2979 participants in the tramadol alone groups and 1555 participants in the placebo control groups contributed to the meta‐analyses of participants withdrawn or dropped out because of adverse events (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>; <a href="./references#CD005522-bbs2-0019" title="SchnitzerTJ , KaminM , OlsonWH . Tramadol allows reduction of naproxen dose among patients with naproxen‐responsive osteoarthritis pain: a randomized, double‐blind, placebo‐controlled study. Arthritis &amp; Rheumatism1999;42(7):1370‐7. ">Schnitzer 1999</a>). Two trials with 350 participants in the tramadol in combination with acetaminophen groups and 264 participants in the placebo control groups contributed to the meta‐analyses of participants withdrawn or dropped out because of adverse events (<a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0020" title="SilverfieldJC , KaminM , WuSC , RosenthalN . Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double‐blind, placebo‐controlled, parallel‐group, add‐on study. Clinical Therapeutics2002;24(2):282‐97. ">Silverfield 2002</a>). There were 796 people with adverse events that made them stop the treatment in the 11 trials. </p> <p>We found moderate quality evidence that participants who received tramadol alone had a greater risk of withdrawing from the study because of adverse events compared to participants who received placebo (RR 2.64, 95% CI 2.17 to 3.20; 9 studies, 4533 participants; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). Nineteen out of 100 people withdrew due to adverse events when taking tramadol alone and 7/100 people withdrew due to adverse events when taking a placebo, which corresponded to 12 more people out of 100 people who withdrew due to adverse events. The NNTH to cause one additional participant to withdraw due to adverse events was 9 (95% CI 7 to 12; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). An I<sup>2</sup> statistic of 55% indicated a moderate degree of heterogeneity. Two trials were responsible for the statistical heterogeneity (<a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>). This could be explained by the duration of the <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a> trial, which was two weeks as compared to the 12‐week duration of the other trials, and the population, which was exclusively white as compared to the slightly more diverse population of the other studies. While both trials indicated that participants who received tramadol alone had a greater risk of withdrawing from the study because of adverse events compared to participants who received placebo (<a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>: RR 5.04, 95% CI 2.94 to 8.62; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>: RR 25.73, 95% CI 3.54 to 187.02), they had higher RRs and wider CIs than the other trials. Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and inconsistency (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In one study which was not included in the meta‐analyses, 15 participants withdrew after randomization due to adverse events, 12 of whom were receiving tramadol at the time of their withdrawal (<a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). </p> <p>We found low quality evidence that participants receiving tramadol in combination with acetaminophen had a greater risk of withdrawing from the study due to adverse events compared to participants who received placebo (RR 2.78, 95% CI 1.50 to 5.16; 2 studies, 614 participants; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). Thirteen out of 100 people withdrew due to adverse events when taking tramadol in combination with acetaminophen and 5/100 people withdrew due to adverse events when taking placebo, which corresponded to 8 more people out of 100 people who withdrew due to adverse events. The NNTH to cause one additional participant to withdraw due to adverse events was 13 (95% CI 6 to 44; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). An I<sup>2</sup> statistic of 0% indicated a low degree of heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and imprecision (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005522-sec-0099"> <p><b>Active‐controlled trials</b></p> <p>Six trials with 891 participants in the tramadol alone groups and 496 participants in the active control groups (including acetaminophen, NSAIDs and opioids) contributed to the meta‐analyses of participants withdrawn or dropped out because of adverse events. There were 275 adverse events that made them stop the treatment in the 11 trials. </p> <p>Due to very low quality evidence, we were uncertain whether tramadol alone had a greater risk of withdrawing from the study because of adverse events compared to acetaminophen (RR 5.00, 95% CI 0.27 to 92.62; 1 study, 20 participants; <a href="./full#CD005522-tbl-0003">summary of findings Table 3</a>; <a href="./references#CD005522-bbs2-0003" title="BianchiM , BrogginiM , BalzariniP , BaratelliE , FerrarioP , PaneraiAE , et al. Effects of tramadol on synovial fluid concentrations of substance P and interleukin‐6 in patients with knee osteoarthritis: comparison with paracetamol. International Immunopharmacology2003;3(13‐14):1901‐8. ">Bianchi 2003</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded three times due to unclear risk of bias and serious imprecision (see <a href="./full#CD005522-tbl-0003">summary of findings Table 3</a>). </p> <p>We found low quality evidence that participants receiving tramadol alone had a greater risk of withdrawing from the study because of adverse events compared to NSAIDs (RR 1.88, 95% CI 1.27 to 2.76; 2 studies, 929 participants; <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>). Twenty‐one out of 100 people withdrew due to adverse events when taking tramadol alone and 11/100 people withdrew due to adverse events when taking NSAIDs, corresponding to 10 more people out of 100 people who withdrew due to adverse events. The NNTH to cause one additional participant to withdraw due to adverse events was 10 (95% CI 5 to 33; see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a> for the main comparison). An I<sup>2</sup> statistic of 60% indicated a high degree of heterogeneity. Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and inconsistency (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). </p> <p>We found low quality evidence that participants receiving tramadol alone had an increased risk of withdrawing due to adverse events compared to other opioids (RR 2.26, 95% CI 1.52 to 3.37; 3 studies, 438 participants; <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>; <a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>). Thirty‐one out of 100 people withdrew due to adverse events when taking tramadol alone and 14/100 people withdrew due to adverse events when taking other opioids, corresponding to 17 more people out of 100 people who withdrew due to adverse events. The NNTH to cause one additional withdrawal due to adverse events was 6 (95% CI 3 to 14). An I<sup>2</sup> statistic of 70% indicated a high degree of heterogeneity among studies comparing tramadol alone to other opioids. One trial was responsible for most of the statistical heterogeneity (<a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>). This trial had a short duration of two weeks and a small sample size of 30 participants. It indicated that participants receiving tramadol had a decreased risk of withdrawing due to adverse events compared to other opioids (RR 0.67, 95% CI 0.22 to 2.01), contrary to the findings of the other trials. Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to the unclear risk of bias and inconsistency (see <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>). </p> </section> </section> <section id="CD005522-sec-0100"> <h6 class="title">Serious adverse events</h6> <section id="CD005522-sec-0101"> <p><b>Placebo‐controlled trials</b></p> <p>Seven trials with 2460 participants in the tramadol alone groups and 1153 participants in the placebo control groups contributed to the analysis of participants experiencing any serious adverse event (<a href="./references#CD005522-bbs2-0001" title="BabulN , NoveckR , ChipmanH , RothSH , GanaT , AlbertK . Efficacy and safety of extended‐release, once‐daily tramadol in chronic pain: a randomized 12‐week clinical trial in osteoarthritis of the knee. Journal of Pain Symptom Management2004;28(1):59‐71. ">Babul 2004</a>; <a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0009" title="FleischmannRM , CaldwellJR , RothSH , TesserJR , OlsonW , KaminM . Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double‐blind, placebo‐controlled trial. Current Therapeutic Research, Clinical &amp; Experimental2001;62(2):113‐28. [MEDLINE: 26] ">Fleischmann 2001</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0015" title="MalonneH , CoffinerM , SonetB , SerenoA , VanderbistF . Efficacy and tolerability of sustained‐release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2004;26(11):1774‐82. ">Malonne 2004</a>). One trial with eight participants in the tramadol in combination with acetaminophen groups and seven participants in the placebo control groups contributed to the analysis of participants experiencing any serious adverse event (<a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>). There were 132 people with serious adverse events in these eight trials. Serious adverse events reported in the tramadol groups included unstable angina, chest pain, breast cancer, diverticulitis, grand mal convulsions, prostate cancer, popliteal bursitis, small intestinal obstruction, cholelithiasis, pancreatitis and abdominal pain. However, authors of the trials mentioned only a few serious adverse events that may have been related to tramadol use. These were syncope, subendocardial myocardial infraction, renal insufficiency combined with an elevation of liver enzymes with inflammation of the liver, gastritis and drug withdrawal syndrome. </p> <p>We found low quality evidence that participants receiving tramadol alone had a greater risk of developing serious adverse events compared to participants who received placebo (RR 1.78, 95% CI 1.11 to 2.84; 7 studies, 3612 participants; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). Three out of 100 people developed serious adverse events when taking tramadol alone and 2/100 people developed serious adverse events when taking a placebo, corresponding to 1 more person out of 100 people who developed serious adverse events. The NNTH to cause one additional participant to experience a serious adverse event was 68 (95% CI 29 to 477; <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). An I<sup>2</sup> statistic of 0% indicated low heterogeneity between trials. Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to unclear risk of bias and imprecision (see <a href="./full#CD005522-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In one study which was not included in the meta‐analyses, one serious adverse event occurred during the double‐blind phase of the study (atrial flutter in one participant with a history of supraventricular tachycardia who received tramadol 150 mg) (<a href="./references#CD005522-bbs2-0021" title="ThorneC , BeaulieuAD , CallaghanDJ , O'MahonyWF , BartlettJM , KnightR , et al. A randomized, double‐blind, crossover comparison of the efficacy and safety of oral controlled‐release tramadol and placebo in patients with painful osteoarthritis. Pain Research &amp; Management2008;13(2):93‐102. ">Thorne 2008</a>). </p> <p>We found low quality evidence that no serious adverse events were reported in a study of tramadol in combination with acetaminophen compared to placebo (1 study, 15 participants; <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to serious imprecision (see <a href="./full#CD005522-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD005522-sec-0102"> <p><b>Active‐controlled trials</b></p> <p>Seven trials with 348 participants in the tramadol groups and 350 participants in the active control groups evaluated the number of participants experiencing serious adverse events but only two contributed to the meta‐analyses since five trials did not report any serious adverse events. There were five people with serious adverse events in these seven trials. Some of the serious adverse events were gastrointestinal bleeding and severe pancreatitis. Due to very low quality evidence, we were uncertain whether tramadol alone compared to NSAIDs had an increased risk of developing serious adverse events (RR 0.21, 95% CI 0.01 to 4.34; 2 studies, 188 participants; <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>; <a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0017" title="PavelkaK , PeliskovaZ , StehlikovaH , RatcliffeS , RepasC . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clinical Drug Investigation1998;16(6):421‐9. ">Pavelka 1998</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded three times due to unclear risk of bias and serious imprecision (see <a href="./full#CD005522-tbl-0004">summary of findings Table 4</a>). </p> <p>Similarly, due to very low quality evidence, we were uncertain whether participants who received tramadol alone had an increased risk of developing serious adverse events compared to participants who received other opioids (RR 7.42, 95% CI 0.39 to 141.00; 4 studies, 495 participants; <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>; <a href="./references#CD005522-bbs2-0004" title="BirdHA , HillJ , StratfordME , FennGC , WrightV , FleischmannRM , et al. A double‐blind cross‐over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. Journal of Drug Development &amp; Clinical Practice1995;7(7):181‐8. [MEDLINE: 25] ">Bird 1995</a>; <a href="./references#CD005522-bbs2-0012" title="JensenEM , GinsbergF . Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: a short term double‐blind study. Drug Investigation1994;8(4):211‐8. ">Jensen 1994</a>; <a href="./references#CD005522-bbs2-0013" title="KarlssonM , BerggrenA . Efficacy and safety of low‐dose transdermal buprenorphine patches (5, 10, and 20 pg/h) versus prolonged‐release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12‐Week, randomized, open label, controlled, parallel‐group noninferiority study. Clinical Therapeutics2009;31(3):503‐13. ">Karlsson 2009</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded three times due to unclear risk of bias and serious imprecision (see <a href="./full#CD005522-tbl-0005">summary of findings Table 5</a>). </p> <p>We found low quality evidence that there was no risk of developing serious adverse events for both the participants who received tramadol in combination with acetaminophen and those who received NSAIDs (1 study, 15 participants; <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>; <a href="./references#CD005522-bbs2-0018" title="PeevaE , BealsCR , BologneseJA , KivitzAJ , TaberL , HarmanA , et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis and Cartilage2010;18:646‐53. ">Peeva 2010</a>). Applying the GRADE criteria to the overall quality of the evidence, we downgraded twice due to serious imprecision (see <a href="./full#CD005522-tbl-0006">summary of findings Table 6</a>). </p> </section> </section> </section> </section> <section id="CD005522-sec-0103"> <h4 class="title">Minor outcomes</h4> <section id="CD005522-sec-0104"> <h5 class="title">Symptoms of opioid dependence: withdrawal symptoms and propensity for abuse</h5> <p>Four trials reported withdrawal symptoms or the propensity for abuse, or both (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>). However, only one trial provided the data required to contribute to the systematic review (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>). This trial assessed propensity for abuse using the Drug Liking Index, a 9‐point scale. There was no difference between treatment groups in these scores. For the number of participants who liked the drug effect, tramadol had similar harms compared to NSAIDs (RR 1.03, 95% CI 0.62 to 1.74). Another trial reported that there was no evidence of abuse, but did not mention how it was assessed (<a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>). </p> <p>The other trials assessed this variable in various ways. One trial assessed the psychic dependence using the 49‐item Short Form Addiction Research Center Inventory questionnaire and the 16‐item Physical Dependence Questionnaire (PDQ) (<a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>). The rates of 12 related symptoms were different among treatment groups. About 5% to 10% more participants in the tramadol group reported these symptoms compared to the placebo group. In one of the studies, physical dependence was assessed using a 16‐item PDQ, where there was one serious adverse event related to study treatment and three drug withdrawal syndromes (non‐serious adverse events) in the tramadol group (<a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>). Thus, 4/815 (0.5%) participants in the tramadol group reported this event. There was a different frequency of physical dependence symptoms between treatment groups one week after discontinuation. </p> <p>Two trials excluded participants that had any history of substance abuse (<a href="./references#CD005522-bbs2-0002" title="BeaulieuAD , PelosoPM , HaraouiB , BensenW , ThomsonG , WadeJ , et al. Once daily, controlled‐release tramadol and sustained‐release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Research &amp; Management2008;13(2):103‐10. ">Beaulieu 2008</a>; <a href="./references#CD005522-bbs2-0007" title="EmkeyR , RosenthalN , WuSC , JordanD , KaminM . Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double‐blind, placebo‐controlled trial. Journal of Rheumatology2004;31(1):150‐6. ">Emkey 2004</a>), and two other trials excluded participants who had had substance abuse in the past six months (<a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005522-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005522-sec-0105"></div> <section id="CD005522-sec-0106"> <h3 class="title" id="CD005522-sec-0106">Summary of main results</h3> <p>In our systematic review and meta‐analyses, we found tramadol alone or in combination with acetaminophen demonstrated no clinically important difference compared to placebo in terms of mean pain relief and improvement of physical function in people with OA. The benefits were small, and may not have been clinically important since the 4‐point improvement in pain was lower than the MCID that we defined as 20 points on a 100‐point scale, although there were slightly more people in the tramadol group who were clinically important responders for both pain and physical function. Adverse events were also higher for participants using tramadol compared to placebo, which may limit the usefulness of tramadol. The quality of this evidence was moderate for benefit outcomes and low to moderate for harm outcomes for placebo‐controlled trials, mostly because of unclear risk of bias, as well as imprecision, especially for the harm outcomes. The quality of the evidence was very low to moderate for active‐controlled trials, mostly because of unclear risk of bias, imprecision and inconsistency. </p> <p>Tramadol alone had similar benefits to other opioids in terms of pain relief and showed a small benefit in terms of physical function compared to other opioids, although probably not clinically important. The quality of this evidence was moderate, due to the unclear risk of bias in included trials. Tramadol alone showed lower benefits than NSAIDs for pain and physical function. However, these benefits were only small, and not clinically important. The quality of this evidence was moderate for pain and low for physical function, due to the risk of bias, as well as imprecision in the physical function analyses. Tramadol in combination with acetaminophen had similar benefits to NSAIDs and opioids for pain and physical function. The quality of this evidence was low to moderate, due to the unclear risk of bias and imprecision. Tramadol alone had similar harms to NSAIDs and opioids, except for withdrawals due to adverse events which were higher for tramadol compared to these controls, and overall adverse events which were higher for tramadol compared to NSAIDs. Tramadol in combination with acetaminophen also had similar harms to NSAIDs. Studies in which participants received tramadol alone had more adverse events than studies in which participants received tramadol in combination with acetaminophen, when compared to placebo. This could be explained by the higher dose of tramadol in the studies in which participants received tramadol alone, compared to a lower dose in studies of tramadol in combination with acetaminophen. The quality of the evidence was very low to moderate because of unclear risk of bias, imprecision of estimates and inconsistency between trials. Although a higher propensity for abuse when using tramadol was not established, it was rarely studied, which precluded any conclusions being made. </p> </section> <section id="CD005522-sec-0107"> <h3 class="title" id="CD005522-sec-0107">Overall completeness and applicability of evidence</h3> <p>This review had several limitations. Most trials were short in duration, with no trials that were longer than 13 weeks. The trials also varied in terms of duration (i.e. range of one week to three months) with a mean duration of two months. Trials allowed participants to take a wide range of dosages of tramadol (i.e. 37.5 mg/day to 400 mg/day) and rarely reported the mean dose of tramadol actually received by participants. Only four studies compared different doses of tramadol (<a href="./references#CD005522-bbs2-0006" title="DeLemosBP , XiangJ , BensonC , GanaTJ , PascualML , RosannaR , et al. Tramadol hydrochloride extended‐release once‐daily in the treatment of osteoarthritis of the knee and/or hip: a double blind, randomized, dose‐ranging Trial. American Journal of Therapeutics2011;18:216‐26. ">DeLemos 2011</a>; <a href="./references#CD005522-bbs2-0008" title="FishmanR , KistlerCJ , EllerbuschMT , AparicioRT , SwamiSS , ShirleyME , et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once‐daily tramadol (tramadol Contramid(R) OAD). Journal of Opioid Management2007;5:273‐80. ">Fishman 2007</a>; <a href="./references#CD005522-bbs2-0011" title="FloreteOG , XiangJ , VorsangerGJ . Effects of extended‐release tramadol on pain‐related sleep parameters in patients with osteoarthritis. Expert Opinion Pharmacotherapy2008;9(11):1817‐27. GanaTJ , PascualML , FlemingRR , ScheinJR , JanagapCC , XiangJ , VorsangerGJ , 023 Study Group. Extended‐release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Curr Med Res Opin2006;22(7):1391‐1401. KosinskiM , JanagapC , GajriaK , ScheinJ , FreedmanJ . Pain relief and pain‐related sleep disturbance with extended‐release tramadol in patients with osteoarthritis. Current Medical Research and Opinion2007;23(7):1615‐26. VorsangerG , XiangJ , JordanD , FarrellJ . Post hoc analysis of a randomized, double‐blind, placebo‐controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clinical Therapeutics2007;29(Suppl):2520‐35. ">Gana 2006</a>; <a href="./references#CD005522-bbs2-0014" title="KeanWF , BouchardS , GossenER . Women with pain due to osteoarthritis: the efficacy and safety of a once‐daily formulation of tramadol. American Academy of Pain Medicine2009;10(6):1001‐11. ">Kean 2009</a>), but doses were pooled in this review since they did not show different results. Most studies permitted additional use of analgesics, usually for pain other than due to OA. Some trials also permitted the use of other cointerventions such as physical therapy if its use was stable during the study. The inclusion of these cointerventions could have influenced the results. </p> <p>Participants were predominantly women, with a mean age of 63 years and with moderate to severe pain, which represents most people with OA. Even though this review included trials for OA of the knee or hip (or both), it is important to note that a significant proportion of the trials were conducted with participants with knee OA only (13 studies including participants with knee or hip OA and nine studies with knee OA). </p> <p>Most studies were conducted in high‐income countries. Studies were conducted in North America (13 studies) and Europe (seven studies, with one of these in both North America and Europe), Asia (two studies) and Africa (one study). Two studies were conducted in low‐ and middle‐income countries (i.e. Romania and South Africa) (<a href="./references#CD005522-bbs2-0005" title="BurchF , FishmanR , MessinaN , CorserB , RadulescuF , SarbuA , et al. A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Journal of Pain and Symptom Management2007;34(3):328‐38. ">Burch 2007</a>; <a href="./references#CD005522-bbs2-0022" title="Wilder‐SmithCH , HillL , SpargoK , KallaA . Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain2001;91(1‐2):23‐31. ">Wilder‐Smith 2001</a>). </p> <p>Thirteen studies included predominantly white participants while one study included predominantly African participants (study in South Africa) and eight studies did not mention it in their inclusion criteria or results. Since there are complex pain disparities related to ethnicity (<a href="./references#CD005522-bbs2-0060" title="GreenCR , AndersonKO , BakerTA , CampbellLC , DeckerS , FillingimRB , et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Medicine2003;4(3):277‐94. ">Green 2003</a>), and there are ethnic differences in the experience of chronic pain (<a href="./references#CD005522-bbs2-0083" title="RileyJLIII , WadeJB , MyersCD , SheffieldD , PapasRK , PriceDD . Racial/ethnic differences in the experience of chronic pain. Pain2002;100(3):291‐8. ">Riley 2002</a>), findings of included studies may not be applicable to people with OA of all races and ethnicities. </p> <p>Three studies were conducted with participants who had previously failed other treatments or benefited from other treatments, which may add to clinical heterogeneity between studies. All studies listed multiple morbidities as exclusion criteria. Therefore, review findings may not be applicable to people with OA who have multiple morbidities. It is known that RCTs regularly exclude participants who have multiple morbidities, which is not representative of the general population that a physician would encounter in clinical practice. Findings that are applied in clinical practice should consider the complexity of effective treatment of these participants (<a href="./references#CD005522-bbs2-0058" title="FortinM , DionneJ , PinhoG , GignacJ , AlmirallJ , LapointeL . Randomized controlled trials: do they have external validity for patients with multiple comorbidities?. Annals of Family Medicine2006;4(2):104‐8. ">Fortin 2006</a>). </p> <p>The included studies did not permit analysis of specified outcomes in this subset of the population. In the included studies, women of childbearing age were regularly excluded if they were pregnant, lactating or not using adequate contraception. The findings of this review may not be applicable to these women. </p> <p>Based on the analyzed evidence, further research about the benefits and harms of tramadol for people with OA should include participants from different ethnicities and with multiple morbidities. Other desirable characteristics are: more head‐to‐head comparisons with active comparators, relevant outcomes recommended for OA, and study designs to accomplish low levels of risk of bias, and that are independently funded. </p> </section> <section id="CD005522-sec-0108"> <h3 class="title" id="CD005522-sec-0108">Quality of the evidence</h3> <p>Most of the trials were funded by the pharmaceutical industry and it was not possible to explore the role of this factor in explaining the estimated treatment effect due to the low number of trials that were not funded by industry. Many trials also had an unclear risk of bias for allocation concealment, blinding of personnel and selective outcome reporting, and a few of the trials were at high risk of bias for incomplete outcome data. </p> <p>Some of the most important factors in determining the analgesic benefits and harms of tramadol are the dose being tested and the duration of the treatment. In this systematic review, the mean dose of tramadol varied between trials (range 37.5 mg to 400 mg daily), as well as the mean length of the trials of 57 days varied (3 to 91 days), which may explain some of the heterogeneity found in some analyses. </p> <p>There was no substantive clinical heterogeneity (i.e. there were no important differences in sample, intervention or control group characteristics) but some comparisons showed moderate to high levels of heterogeneity between trials. However, given the acceptable lack of clinical heterogeneity, all trials were kept in the analyses. </p> <p>Few studies assessed withdrawal symptoms or propensity for abuse and in various ways which precluded pooling this data. Since studies excluded participants with a history of substance abuse, it could lead to under‐reporting of the problem since participants who may abuse tramadol are likely to have a history of substance abuse. Studies should be conducted to address this potential adverse event in a more standardized manner. Studies addressing this issue should also be conducted for longer duration than 91 days (13 weeks), which was the longest duration in the trials assessed in this systematic review. </p> </section> <section id="CD005522-sec-0109"> <h3 class="title" id="CD005522-sec-0109">Potential biases in the review process</h3> <p>We performed a systematic literature search, which included both published (i.e. from various electronic databases) and unpublished trials (i.e. from protocol registries). This approach helped to ensure that all publications were identified and thus reduced potential publication bias. However, there are eight protocols of completed trials for which we could not obtain data, which remains a limitation (<a href="./references#CD005522-bbs1-0003" title="">Studies awaiting classification</a>). We contacted authors of each trial and protocol at least twice to obtain any missing information. In the cases of these protocols, we could not obtain more data. The funnel plot for trials contributing data for the pain relief effect of tramadol compared to placebo showed no publication bias, but there is still potentially a publication bias since we could not include any data from the protocols for which data was not published (see <a href="./appendices#CD005522-sec-0118">Appendix 2</a> with list of studies and authors/companies that were reached). </p> <p>Two review authors independently performed selection of trials, risk of bias assessment and data extraction, and consulted a third review author if an agreement could not be reached. This process helped to ensure the accuracy of data and to reduce the risk of bias (<a href="./references#CD005522-bbs2-0057" title="EggerM , SmithGD . Principles of and procedures for systematic reviews. Systematic reviews in health care: meta‐analysis in context. BMJ Publishing Group, 2001:23‐42. ">Egger 2001</a>; <a href="./references#CD005522-bbs2-0061" title="GøtzschePC , HróbjartssonA , MaricK , TendalB . Data extraction errors in meta‐analyses that use standardized mean differences. JAMA2007;298(4):430–7. ">Gøtzsche 2007</a>). </p> </section> <section id="CD005522-sec-0110"> <h3 class="title" id="CD005522-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>The previously published Cochrane systematic review on tramadol for OA included 11 trials that compared tramadol to placebo and other active controls (Cepeda 2006). We included data from 10 of these in our meta‐analyses and included data from 10 additional trials. Compared to this earlier published review, results showed slightly less pain relief (4 more points on a 100‐mm VAS for tramadol alone and tramadol in combination with acetaminophen versus 8.5 more points on a 100‐mm VAS for trials of tramadol alone and tramadol in combination with acetaminophen) and slightly higher physical function compared to placebo (4 out of 100 on a WOMAC Function scale for tramadol alone and tramadol in combination with acetaminophen versus 3 out of 100 points on a VAS for trials of tramadol alone and tramadol in combination with acetaminophen). We included 11 more trials compared to two other systematic reviews (<a href="./references#CD005522-bbs2-0025" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis Cartilage2007;15(8):957‐65. ">Avouac 2007</a>; Cepeda 2006), which may be the reason that we found smaller effects when estimating pain relief. </p> <p>The current review also showed that tramadol was somewhat less effective in reducing pain and improving physical function compared to NSAIDs, which is a new finding compared to older systematic reviews of tramadol and other opioids, which could not reach conclusions on this comparison because of the small number of trials (<a href="./references#CD005522-bbs2-0025" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis Cartilage2007;15(8):957‐65. ">Avouac 2007</a>; Cepeda 2006). </p> <p>The current review showed that the same types of adverse effects were reported for tramadol compared to placebo in the last published Cochrane Review of tramadol for OA (Cepeda 2006) and others (<a href="./references#CD005522-bbs2-0025" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis Cartilage2007;15(8):957‐65. ">Avouac 2007</a>). </p> <p>As with the previous Cochrane Review, it was difficult to provide a robust estimate of adverse events when tramadol was compared to other drugs as there were few trials (Cepeda 2006). However, this review found an increased risk of withdrawals due to adverse events in the tramadol group compared to other NSAIDs and opioids. Similar to other systematic reviews of tramadol, there was not enough controlled trial evidence to make conclusions about withdrawal symptoms and propensity for abuse, so although observational evidence suggested that tramadol may have been well tolerated compared to other opioids, the same precautions against addiction and abuse should be taken as with other opioids. Long term RCTs of high quality are needed to investigate further potential harms for people with OA compared to placebo and other active treatments, such as acetaminophen, NSAIDs and other opioids. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005522-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. OA: osteoarthritis; RCT: randomized controlled trial." data-id="CD005522-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. OA: osteoarthritis; RCT: randomized controlled trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD005522-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD005522-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Tramadol versus placebo, outcome: 1.1 Pain." data-id="CD005522-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Tramadol versus placebo, outcome: 1.1 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tramadol versus placebo, Outcome 1 Pain." data-id="CD005522-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tramadol versus placebo, Outcome 1 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tramadol versus placebo, Outcome 2 Physical function." data-id="CD005522-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tramadol versus placebo, Outcome 2 Physical function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tramadol versus placebo, Outcome 3 Number of participants experiencing any adverse events." data-id="CD005522-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tramadol versus placebo, Outcome 3 Number of participants experiencing any adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tramadol versus placebo, Outcome 4 Number of participants who withdrew due to adverse events." data-id="CD005522-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tramadol versus placebo, Outcome 4 Number of participants who withdrew due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tramadol versus placebo, Outcome 5 Number of participants experiencing any serious adverse events." data-id="CD005522-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tramadol versus placebo, Outcome 5 Number of participants experiencing any serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 1 Pain." data-id="CD005522-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 1 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 2 Physical function." data-id="CD005522-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 2 Physical function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 3 Function: overall assessment." data-id="CD005522-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 3 Function: overall assessment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 4 Number of participants experiencing any adverse even." data-id="CD005522-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 4 Number of participants experiencing any adverse even. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 5 Number of participants who withdrew due to adverse events." data-id="CD005522-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 5 Number of participants who withdrew due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 6 Number of participants experiencing any serious adverse events." data-id="CD005522-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 6 Number of participants experiencing any serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005522-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/urn:x-wiley:14651858:media:CD005522:CD005522-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_t/tCD005522-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tramadol versus active treatment, Outcome 7 Symptoms of opioid dependence: propensity for abuse." data-id="CD005522-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Tramadol versus active treatment, Outcome 7 Symptoms of opioid dependence: propensity for abuse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/media/CDSR/CD005522/image_n/nCD005522-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tramadol alone compared with placebo for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tramadol alone compared with placebo for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> osteoarthritis of the hip or knee, or both </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: 0–100‐mm VAS pain intensity where 0 = no pain </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 54.3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 4 points lower (3 lower to 5 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3972 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 4% absolute improvement (95% CI 3% to 5% improvement),<sup>b</sup> 7% relative improvement (6% to 9% improvement), </p> <p>SMD –0.25 (95% CI –0.32 to –0.18)<sup>f</sup> </p> <p>NNTB 13 (95% CI 10 to 18)<sup>g</sup> </p> <p>A cross‐over study (Thorne 2008), which was not included in the meta‐analyses, showed improvement in pain in the intervention group compared to the placebo group (mean ± SD: 189.0 ± 105.0 versus 230.0 ± 115.4; P = 0.00). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (3 more to 6 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (95% CI 1.30 to 1.60)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: WOMAC Physical Function (scale 0 to 1700) </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was 1059</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was 68 points lower (41 lower to 99 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2550 (5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean function: 4% absolute improvement (95% CI 2% to 6% improvement),<sup>b</sup> 6% relative improvement (95% CI 4% to 9% improvement),<sup>f</sup> </p> <p>SMD –0.20 (95% CI –0.29 to –0.12),</p> <p>NNTB 13 (95% CI 9 to 21)<sup>g</sup> </p> <p>A cross‐over study (Thorne 2008), which was not included in the meta‐analyses, showed improvement in physical function in the intervention group compared to the placebo group (mean ± SD: 632.4 ± 361.3 vs 727.4 ± 383.4; P = 0.02). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (3 more to 8 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b> (95% CI 1.19 to 1.50)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse events</b> </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>492 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>659 per 1000</b><br/> (610 to 718) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b> <br/> (95% CI 1.24 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2039 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17% absolute worsening (95% CI 12% more to 23% more),</p> <p>34% relative worsening (95% CI 24% more to 46% more),</p> <p>NNTH 6 (95% CI 5 to 9)</p> <p>A cross‐over study (Thorne 2008), which was not included in the meta‐analyses, showed that there was little or no difference in the total number of adverse events between the intervention group (79.8%) and placebo group (65.9%) (P = 0.08). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b><br/> (159 to 235) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.64</b> <br/> (95% CI 2.17 to 3.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4533 (9 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12% absolute worsening (95% CI 9% more to 16% more),</p> <p>164% relative worsening (95% CI 117% more to 220% more),</p> <p>NNTH 9 (95% CI 7 to 12)</p> <p>In a cross‐over study (Thorne 2008), which was not included in the meta‐analyses, 15 participants withdrew after randomization due to adverse events, 12 of which were in the intervention group at the time of withdrawal. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 1 week to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (21 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> <br/> (95% CI 1.11 to 2.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3612 (7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% absolute worsening (95% CI 0% more to 4% more),</p> <p>78% relative worsening (95% CI 11% more to 184% more),</p> <p>NNTH 68 (95% CI 29 to 477)</p> <p>In a cross‐over study (Thorne 2008), which was not included in the meta‐analyses, 1 serious adverse event occurred in a participant in the intervention group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RCT:</b> randomized controlled trial;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference; <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMDs and SEs, and binary outcomes expressed as RRs. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute improvement on a common scale (e.g. 100 mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level due to unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the CMSG Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>).<br/> <sup>h</sup>Downgraded one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tramadol alone compared with placebo for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with placebo for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen compared with placebo for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol in combination with acetaminophen </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 100 where 0 = no pain) </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 48.3 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 4 points lower (2 lower to 6 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>614 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 4% absolute improvement (95% CI 2% to 6% improvement),b</p> <p>8% relative improvement (95% CI 4% to 12% improvement),<sup>f</sup> </p> <p>SMD –0.28 (95% CI –0.45 to –0.12), NNTB 14 (95% CI 9 to 33)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (2 more to 9 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> (95% CI 1.29 to 2.29)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: self‐report questionnaire WOMAC Physical Function (scale 0 to 10, where 0 = no limitation) </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was</p> <p>5.9 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was 0.4 points lower (0.2 lower to 0.7 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>614 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean function: 4% absolute improvement (95% CI 2% to 7% improvement),<sup>b</sup> </p> <p>7% relative improvement (95% CI 3% to 12% improvement),<sup>f</sup> </p> <p>SMD –0.27 (95% CI –0.43 to –0.11), NNTB 12 (95% CI 8 to 30)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 more out of 100 (2 more to 9 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b> (95% CI 1.20 to 1.90)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>447 per 1000</b><br/> (309 to 646) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.91</b> (95% CI 1.32 to 2.76)<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22% absolute worsening (95% CI 8% more to 41% more),</p> <p>91% relative worsening (95% CI 32% more to 176% more),</p> <p>NNTH 5 (95% CI 3 to 14)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b><br/> (68 to 235) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.78</b> </p> <p>(95% CI 1.50 to 5.16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8% absolute worsening (95% CI 2% more to 19% more),</p> <p>178% relative worsening (95% CI 50% more to 416% more),</p> <p>NNTH 13 (95% CI 6 to 44)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 10 days to 13 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported: not estimable, NNTH not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference; <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute improvement on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level due to unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>The relative improvement percentage was defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>).<br/> <sup>h</sup>Downgraded one level for imprecision (wide CI).<br/> <sup>i</sup>Downgraded two levels for serious for imprecision (no events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with placebo for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tramadol alone compared with acetaminophen for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol alone compared with acetaminophen for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> acetaminophen </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>acetaminophen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 100 where 0 = no pain) </p> <p>Follow‐up: 1 week</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 38 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 2 higher (12 lower to 16 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 2% absolute worsening (95% CI 16% worsening to 12% improvement),<sup>b</sup> 5% relative worsening (95% CI 42% worsening to 32% improvement),<sup>g</sup> </p> <p>SMD 0.13 (–0.80 to 1.06),</p> <p>NNTB not applicable<sup>h</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 less out of 100 (8 less to 20 more)in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (95% CI 0.11 to 3.22)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: 1 week</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.00</b><br/> (95% CI 0.27 to 92.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute improvement on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Downgraded two levels for serious imprecision (few events and wide CI).<br/> <sup>g</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>h</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement was defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tramadol alone compared with acetaminophen for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tramadol alone compared with NSAIDs for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol alone compared with NSAIDs for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 500 where 0 = no pain) </p> <p>Follow‐up: range 4 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 300.8 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 22 points higher (7 higher to 37 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>952 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 4% absolute worsening (95% CI 1% to 7% worsening),<sup>b</sup> </p> <p>7% relative worsening (95% CI 2% to 12% worsening),<sup>f</sup> </p> <p>SMD 0.21 (95% CI 0.07 to 0.36),</p> <p>NNTB 12 (95% CI 7 to 35)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (8 less to 2 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (95% CI 0.53 to 0.88)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: self‐report questionnaire WOMAC Physical Function (scale 0 to 1700, where 0 = no limitation) </p> <p>Follow‐up: range 4 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was 1019 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was</p> <p>82 higher (32 higher to 131 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>952 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean physical function: 5% absolute worsening (95% CI 2% to 8% worsening),<sup>b</sup> </p> <p>8% relative worsening (95% CI 3% to 13% worsening),<sup>f</sup> </p> <p>SMD 0.23 (95% CI 0.09 to 0.37),</p> <p>NNTB 11 (95% CI 7 to 27)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (7 less to 2 less) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> (95% CI 0.59 to 0.88)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse even</b>t </p> <p>Follow‐up: 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>591 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>774 per 1000</b><br/> (609 to 987) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b><br/> (95% CI 1.03 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18% absolute worsening (95% CI 2% more to 40% more),</p> <p>31% relative worsening (95% CI 3% more to 67% more),</p> <p>NNTH 6 (95% CI 3 to 57)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 8 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b><br/> (142 to 309) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.88</b><br/> (95% CI 1.27 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>929 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% absolute worsening (95% CI 3% more to 20% more),</p> <p>88% relative worsening (95% CI 27% more to 176% more), NNTH 10 (95% CI 5 to 33)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 4 weeks to 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b><br/> (0 to 90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b><br/> (95% CI 0.01 to 4.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>).<br/> <sup>h</sup>Downgraded one level for inconsistency.<br/> <sup>i</sup>Downgraded two levels for serious imprecision (few events and wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Tramadol alone compared with NSAIDs for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tramadol alone compared with other opioids for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol alone compared with other opioids for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol alone </p> <p><b>Comparison:</b> other opioids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Other opioids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol alone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 100 mm where 0 = no pain) </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 36 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 3 points lower (9 lower to 3 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>411 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 3% absolute improvement (95% CI 3% worsening to 9% improvement),<sup>b</sup> </p> <p>8% relative improvement (95% CI 8% worsening to 25% improvement),<sup>f</sup> </p> <p>SMD –0.11 (95% CI –0.33 to 0.12)</p> <p>NNTB not applicable<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 more out of 100 (4 less to 11 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> (95% CI 0.83 to 1.48)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function</b> assessed with participants rating their overall assessment of the therapy at end of study as good or better </p> <p>Follow‐up: 2 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>505 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b><br/> (525 to 848) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> (95% CI 1.04 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16% absolute improvement (95% CI 2% more to 34% more),<sup>b</sup> </p> <p>32% relative improvement (95% CI 4% more to 68% more),<sup>f</sup> </p> <p>NNTB: 7 (95% CI 3 to 50)<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b><br/> (471 to 612) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (95% CI 0.87 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>e,h,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% absolute worsening (95% CI 7% fewer to 7% more),</p> <p>1% relative worsening (95% CI 13% fewer to 13% more),</p> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>311 per 1000</b><br/> (209 to 464) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.26</b> </p> <p>(95% CI 1.52 to 3.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438 (3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17% absolute worsening (95% CI 7% more to 33% more),</p> <p>126% relative worsening (95% CI 52% more to 237% more),</p> <p>NNTH 6 (95% CI 3 to 14)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: range 2 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.42</b><br/> (95% CI 0.39 to 141.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>495 (4 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>e,j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% absolute worsening (95% CI 0% fewer to 0% fewer),</p> <p>642% relative worsening (95% CI 13% fewer to 41% more),</p> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">mumusculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement was defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results.<br/> <sup>h</sup>Downgraded one level for inconsistency.<br/> <sup>i</sup>Downgraded one level for imprecision (wide CI).<br/> <sup>j</sup>Downgraded two levels for serious imprecision (few events and wide CI). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tramadol alone compared with other opioids for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol in combination with acetaminophen </p> <p><b>Comparison:</b> NSAIDs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 10 mm where 0 = no pain) </p> <p>Follow‐up: range 8 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 5.2 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was 0.3 points higher (0.4 lower to 0.9 higher)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>226 (2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 3% absolute worsening (95% CI 9% worsening to 4% improvement),<sup>b</sup> </p> <p>6% relative worsening (95% CI 17% worsening to 8% improvement),<sup>f</sup> </p> <p>SMD 0.12 (–0.16 to 0.39),</p> <p>NNTB not applicable<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (15 less to 6 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> (95% CI 0.68 to 1.13)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Physical function</b> assessed with: WOMAC Physical Function on a 96‐point scale </p> <p>Follow‐up: 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function was 21.40</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function in the intervention group was 2 points higher (2 lower to 6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>91 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean physical function: 2% absolute worsening (95% CI 7% worsening to 2% improvement),<sup>b</sup> </p> <p>9% relative worsening (95% CI 28% worsening to 9% improvement),<sup>f</sup> </p> <p>SMD 0.20 (–0.21 to 0.61)</p> <p>NNTB not applicable<sup>g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 less out of 100 (13 less to 7 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b> (95% CI 0.41 to 1.32)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>702 per 1000</b><br/> (522 to 942) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b><br/> (95% CI 0.87 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% absolute worsening (95% CI 8% improvement to 34% worsening),</p> <p>17% relative worsening (95% CI 13% improvement to 57% worsening),</p> <p>NNTH not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> <p>Follow‐up: 3 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not estimable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome;<b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference; <b>WOMAC:</b> Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. The corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Relative improvement percentage defined as relative to the control group risk at baseline.<br/> <sup>g</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results.<br/> <sup>h</sup>Downgraded one level for imprecision (wide CI).<br/> <sup>i</sup>Downgraded two levels for serious imprecision (no events). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with NSAIDs for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005522-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> osteoarthritis </p> <p><b>Settings:</b> outpatient clinics </p> <p><b>Intervention:</b> tramadol in combination with acetaminophen </p> <p><b>Comparison:</b> other opioids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk**</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk**</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Other opioids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tramadol in combination with acetaminophen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> assessed with: self‐report VAS pain intensity (scale 0 to 10 mm where 0 = no pain) </p> <p>Follow‐up: 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain was 6.4 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain of the intervention group was 0.3 points higher (1.8 higher to 1.3 lower)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean pain: 3% absolute worsening (95% CI 18% worsening to 13% improvement),<sup>b</sup> </p> <p>5% relative worsening (95% CI 28% worsening to 20% improvement),<sup>f</sup> </p> <p>SMD 0.06 (95% CI –0.31, 0.43),</p> <p>NNTB not applicable<sup>h</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 out of 100 improved by 20%<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 less out of 100 (16 less to 13 more) in the intervention group improved by 20%<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> (95% CI 0.67 to 1.27)<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **The assumed and the corresponded <b>risk</b> was calculated from the <b>SMD</b> and <b>SE</b>. </p> <p><b>CI:</b> confidence interval; <b>MCID:</b> minimal clinically important difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio;<b>SD:</b> standard deviation; <b>SE:</b> standard error; <b>SMD:</b> standardized mean difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Continuous outcomes summarized using SMD and SE, and binary outcomes expressed as RR. We used standard inverse‐variance fixed‐effect meta‐analysis to combine the trials in Review Manager 5 (<a href="./references#CD005522-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>).<br/> <sup>b</sup>Absolute effect on a common scale (e.g. 100‐mm, 1700‐point scale) calculated by multiplying the SMD by the SD of the scale (in the control group at baseline) as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 12.6.4; <a href="./references#CD005522-bbs2-0063" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>).<br/> <sup>c</sup>Assumed and corresponding risks calculated from the SMD and SE, with improvement based on an MCID of 20% of the given scale using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/</a>).<br/> <sup>d</sup>RR and its 95% CI calculated using the assumed risk of the control group and corresponding risk of the treatment group. Corresponding risk was divided by the assumed risk.<br/> <sup>e</sup>Downgraded one level for unclear risk of bias (all trials had high or unclear risk of at least one type of bias).<br/> <sup>f</sup>Downgraded one level for imprecision.<br/> <sup>g</sup>Relative improvement percentage is defined as relative to the control group risk at baseline.<br/> <sup>h</sup>NNTB corresponded to the number of participants that needed to be treated to see one participant improve. Improvement defined as reaching an MCID of 20% on the given scale. NNTB calculated using the Wells calculator (from the Cochrane Musculoskeletal Group Editorial office; <a href="http://musculoskeletal.cochrane.org/" target="_blank">musculoskeletal.cochrane.org/ne.org/</a>). It was only calculated for statistically significant results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Tramadol in combination with acetaminophen compared with other opioids for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/full#CD005522-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005522-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tramadol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.32, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tramadol alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.32, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tramadol in combination with acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.45, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.30, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tramadol alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.29, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tramadol in combination with acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.43, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants experiencing any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.26, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tramadol alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.24, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tramadol in combination with acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.32, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants who withdrew due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [2.20, 3.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tramadol alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [2.17, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tramadol in combination with acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [1.50, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants experiencing any serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.11, 2.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Tramadol alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.11, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tramadol in combination with acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tramadol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005522-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tramadol versus active treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tramadol alone vs acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.80, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tramadol alone vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tramadol alone vs other opioids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.33, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Tramadol in combination with acetaminophen vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.16, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Tramadol in combination with acetaminophen vs other opioids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.31, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.09, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Tramadol alone vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.09, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tramadol in combination with acetaminophen vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [‐0.21, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Function: overall assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.04, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tramadol alone vs other opioids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.04, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants experiencing any adverse even <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.96, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Tramadol alone vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.03, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tramadol alone vs other opioids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Tramadol in combination with acetaminophen vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants who withdrew due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [1.57, 2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Tramadol alone vs acetaminophen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.27, 92.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tramadol alone vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.27, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Tramadol alone vs other opioids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.52, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants experiencing any serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.16, 10.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Tramadol alone vs NSAID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tramadol alone vs other opioids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.42 [0.39, 141.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Tramadol in combination with acetaminophen vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Symptoms of opioid dependence: propensity for abuse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.62, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Tramadol alone vs NSAIDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.62, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tramadol versus active treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005522.pub3/references#CD005522-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005522.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005522-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005522-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005522-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005522-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005522-note-0018">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD005522-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD005522-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005522-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005522-note-0017">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005522\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005522\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005522\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005522\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005522\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005522.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005522.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005522.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005522.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005522.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726307676"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005522.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726307681"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005522.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e90782ed5f431',t:'MTc0MDcyNjMwOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 